TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading c:\stnexp4\queries\09585925.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> s l1

SAMPLE SEARCH INITIATED 09:42:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 21792 TO ITERATE

4.6% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 427045 TO 444635
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 C,N

G2 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading c:\stnexp4\queries\09585925.str

L4 STRUCTURE UPLOADED

=> que L4

L5 QUE L4

=> s l4

SAMPLE SEARCH INITIATED 09:43:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 214 TO ITERATE

100.0% PROCESSED 214 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3403 TO 5157
PROJECTED ANSWERS: 406 TO 1154

L6 39 SEA SSS SAM L4

=> d scan

L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(trifluoromethyl)-1H-imidazol-2-yl]methylene]-, (2E)- (9CI)
MF C13 H8 F3 N3 O S

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2E)-4-hydroxy-2-butenylidene]-4-methyl-
, (2Z)- (9CI)
MF C13 H13 N O2 S

Double bond geometry as shown.



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 4H-1,4-Benzothiazine-4-acetic acid, 2,3-dihydro-3-oxo-2-[(2,4,6-trimethoxyphenyl)methylene]-, ethyl ester (9CI)
MF C22 H23 N O6 S



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI)
MF C13 H10 N2 O2 S

Double bond geometry as shown.



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]- (9CI)
MF C22 H22 N4 O2 S



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(acetyloxy)-3-methoxy-5-methylphenyl]methylene]- (9CI)
MF C19 H17 N O4 S



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(3-nitrophenyl)amino]methylene]- (9CI)
MF C15 H11 N3 O3 S



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-methyl-1H-pyrazol-4-yl)methylene]-(9CI)
MF C13 H11 N3 O S



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS

IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2E)-4-(acetyloxy)-2-butenylidene]-4-methyl-, (2Z)- (9CI)
MF C15 H15 N O3 S

Double bond geometry as shown.



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(3-ethyl-2(3H)-benzothiazolylidene)-1-[(3-ethyl-2(3H)-benzothiazolylidene)methyl]ethylidene]-4-(phenylmethyl)-, 1,1-dioxide (9CI)
MF C36 H31 N3 O3 S3



L6 39 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-2-ylmethylene)-, (2Z)- (9CI)
MF C17 H12 N2 O S

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> fil stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.24	1.39

FILE 'STNGUIDE' ENTERED AT 09:44:37 ON 19 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2001 (20010511/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.00	1.39

FILE 'REGISTRY' ENTERED AT 09:49:50 ON 19 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 MAY 2001 HIGHEST RN 336783-59-6
DICTIONARY FILE UPDATES: 18 MAY 2001 HIGHEST RN 336783-59-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading c:\stnexp4\queries\09585925.str

L7 STRUCTURE UPLOADED

=> que L7

L8 QUE L7

=> d l7

L7 HAS NO ANSWERS
L7 STR



G1 C,N

G2 O,S,N

G3 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

Structure attributes must be viewed using STN Express query preparation.

=> y

Y IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l7

SAMPLE SEARCH INITIATED 09:50:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 137 TO ITERATE

100.0% PROCESSED 137 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 2038 TO 3442
PROJECTED ANSWERS: 5 TO 233

L9 5 SEA SSS SAM L7

=> d scan

L9 5 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2E)-4-(acetyloxy)-2-butenylidene]-4-methyl-, (2Z)- (9CI)
MF C15 H15 N O3 S

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L9 5 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-(4-hydroxy-2-methyl-2-butenylidene)-4-methyl-, (?,Z)- (9CI)
MF C14 H15 N O2 S

Double bond geometry as described by E or Z.



L9 5 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[2-(3-methyl-2-benzothiazolinylidene)ethylidene]- (8CI)
MF C19 H16 N2 O S2



L9 5 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2E)-4-hydroxy-2-butenylidene]-4-methyl-
, (2Z)- (9CI)
MF C13 H13 N O2 S

Double bond geometry as shown.



L9 5 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1,3-benzodioxol-5-ylmethylene)-4-methyl-
(9CI)
MF C17 H13 N O3 S



ALL ANSWERS HAVE BEEN SCANNED

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading c:\stnexp4\queries\09585925.str

L10 STRUCTURE UPLOADED

=> que L10

L11 QUE L10

=> d l10

L10 HAS NO ANSWERS
L10 STR



G1 C,N

G2 O,S,N

G3 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

Structure attributes must be viewed using STN Express query preparation.

=> s l10

SAMPLE SEARCH INITIATED 09:51:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 214 TO ITERATE

100.0% PROCESSED 214 ITERATIONS 26 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3403 TO 5157
PROJECTED ANSWERS: 215 TO 825

L12 26 SEA SSS SAM L10

=> d scan

L12 26 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(acetyloxy)-3-methoxy-5-methylphenyl]methylene]- (9CI)
MF C19 H17 N O4 S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L12 26 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2E)-4-hydroxy-2-butenylidene]-4-methyl-, (2Z)- (9CI)
MF C13 H13 N O2 S

Double bond geometry as shown.



L12 26 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 1H-Indole-6-sulfonamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N,N-dimethyl- (9CI)
MF C19 H17 N3 O3 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):edn

'EDN' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l10 ful

FULL SEARCH INITIATED 09:52:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4251 TO ITERATE

100.0% PROCESSED 4251 ITERATIONS 470 ANSWERS
SEARCH TIME: 00.00.02

L13 470 SEA SSS FUL L10

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	134.80	136.19

FILE 'CAPLUS' ENTERED AT 09:52:42 ON 19 MAY 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 May 2001 VOL 134 ISS 22
FILE LAST UPDATED: 18 May 2001 (20010518/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s l13

L14 74 L13

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 74 ANSWERS - CONTINUE? Y/(N):y

L14 ANSWER 1 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:881149 CAPLUS
DOCUMENT NUMBER: 134:42147
TITLE: Preparation and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors
INVENTOR(S): Rafferty, Paul; Calderwood, David; Arnold, Lee D.; Gonzalez Pascual, Beatriz; Ortego Matinez, Jose L.; Perez de Vega, Maria J.; Fernandez, Isabel F.
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075139	A2	20001214	WO 2000-US15324	20000602
WO 2000075139	A3	20010329		

W: AU, BG, BR, CA, CN, CZ, HR, HU, ID, IL, IN, JP, KR, MX, NO, NZ,

PL, RU, SG, SK, TR, UA, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1999-137410 P 19990603
OTHER SOURCE(S): MARPAT 134:42147
GI



I



II

AB Title compds. [I; Q = N, CR2; X = S, O, NOR3; Y = S, O, SO, SO2; R, R1 independently = H, aliph., aryl, hetercyclyl; R2 = H, CH3; R3 = H, COR4; R4 = alkyl, alkenyl, alkynyl, aryl; n = 0, 1; R5 = 7-Cl, 7-CH3, 6-CF3, 6-CH3, 6-Cl, 7-OCH3, 6-CH3CONH, 7-OH, etc.] are prepd. Title compds. and physiol. acceptable salts are inhibitors of receptor tyrosine kinase or non-receptor tyrosine kinase activity which involve in angiogenic process.

Thus, title compds. can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor and can be used to treat cancer and hyperproliferative disorders. Title compd. II was prepd.

IT **312970-19-7P 312970-35-7P 312970-49-3P**
312972-81-9P 312972-84-2P 312973-50-5P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)

RN 312970-19-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-nitro-2-(1H-pyrrol-2-ylmethylene)-, (2Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



544/56-2

RN 312970-35-7 CAPLUS
CN 1H-Pyrrole-1-acetic acid, 2-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-49-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(4-hydroxybutyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-81-9 CAPLUS
CN 2H-1,4-Benzothiazine-3(4H)-thione, 2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312972-84-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-, oxime (9CI) (CA INDEX NAME)



RN 312973-50-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-nitro-2-(1H-pyrrol-2-ylmethylene)-, (2E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **312970-15-3P 312970-16-4P 312970-17-5P**
312970-18-6P 312970-20-0P 312970-21-1P
312970-22-2P 312970-23-3P 312970-24-4P
312970-25-5P 312970-26-6P 312970-27-7P
312970-28-8P 312970-29-9P 312970-30-2P
312970-31-3P 312970-32-4P 312970-33-5P
312970-34-6P 312970-36-8P 312970-37-9P
312970-38-0P 312970-39-1P 312970-40-4P
312970-41-5P 312970-42-6P 312970-43-7P
312970-44-8P 312970-45-9P 312970-46-0P
312970-47-1P 312970-48-2P 312970-50-6P
312970-51-7P 312970-52-8P 312970-53-9P
312970-54-0P 312970-55-1P 312970-56-2P
312970-57-3P 312970-58-4P 312970-59-5P
312970-60-8P 312970-61-9P 312970-62-0P
312970-63-1P 312970-64-2P 312970-65-3P
312970-66-4P 312970-67-5P 312970-68-6P
312970-69-7P 312970-70-0P 312970-71-1P
312970-72-2P 312970-73-3P 312970-74-4P
312970-75-5P 312970-76-6P 312970-77-7P
312970-78-8P 312970-79-9P 312970-80-2P
312970-81-3P 312970-82-4P 312970-83-5P
312970-84-6P 312970-85-7P 312970-86-8P

312970-87-9P 312970-88-0P 312970-89-1P
312970-90-4P 312970-91-5P 312970-92-6P
312970-93-7P 312970-94-8P 312970-95-9P
312970-96-0P 312970-97-1P 312970-98-2P
312970-99-3P 312971-00-9P 312971-01-0P
312971-02-1P 312971-03-2P 312971-04-3P
312971-05-4P 312971-06-5P 312971-07-6P
312971-08-7P 312971-09-8P 312971-10-1P
312971-11-2P 312971-12-3P 312971-13-4P
312971-14-5P 312971-15-6P 312971-16-7P
312971-17-8P 312971-18-9P 312971-19-0P
312971-20-3P 312971-21-4P 312971-22-5P
312971-23-6P 312971-24-7P 312971-25-8P
312971-26-9P 312971-27-0P 312971-28-1P
312971-29-2P 312971-30-5P 312971-31-6P
312971-32-7P 312971-33-8P 312971-34-9P
312971-35-0P 312971-36-1P 312971-37-2P
312971-38-3P 312971-39-4P 312971-40-7P
312971-41-8P 312971-42-9P 312971-43-0P
312971-44-1P 312971-45-2P 312971-46-3P
312971-47-4P 312971-48-5P 312971-49-6P
312971-50-9P 312971-51-0P 312971-52-1P
312971-53-2P 312971-54-3P 312971-55-4P
312971-56-5P 312971-57-6P 312971-58-7P
312971-59-8P 312971-60-1P 312971-61-2P
312971-62-3P 312971-63-4P 312971-64-5P
312971-65-6P 312971-66-7P 312971-67-8P
312971-68-9P 312971-69-0P 312971-70-3P
312971-71-4P 312971-72-5P 312971-73-6P
312971-74-7P 312971-75-8P 312971-76-9P
312971-77-0P 312971-78-1P 312971-79-2P
312971-80-5P 312971-81-6P 312971-82-7P
312971-83-8P 312971-84-9P 312971-85-0P
312971-86-1P 312971-87-2P 312971-88-3P
312971-89-4P 312971-90-7P 312971-91-8P
312971-92-9P 312971-93-0P 312971-94-1P
312971-95-2P 312971-96-3P 312971-97-4P
312971-98-5P 312971-99-6P 312972-00-2P
312972-01-3P 312972-02-4P 312972-03-5P
312972-04-6P 312972-05-7P 312972-06-8P
312972-07-9P 312972-08-0P 312972-09-1P
312972-10-4P 312972-11-5P 312972-12-6P
312972-13-7P 312972-14-8P 312972-15-9P
312972-16-0P 312972-17-1P 312972-18-2P
312972-19-3P 312972-20-6P 312972-21-7P
312972-79-5P 312972-80-8P 312972-85-3P
312972-86-4P 312972-87-5P 312972-88-6P
312972-91-1P 312972-92-2P 312972-93-3P
312972-94-4P 312972-95-5P 312972-96-6P
312972-97-7P 312972-98-8P 312972-99-9P
312973-00-5P 312973-01-6P 312973-02-7P
312973-03-8P 312973-04-9P 312973-05-0P
312973-46-9P 312973-47-0P 312973-48-1P
312973-49-2P 312973-51-6P 312973-52-7P
312973-53-8P 312973-54-9P 312973-55-0P
312973-56-1P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)

RN 312970-15-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-16-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-methoxy-2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-17-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-6-(trifluoromethoxy)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-18-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-methyl-2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-20-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-chloro-2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-21-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-22-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-methyl-2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-23-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-(1H-pyrrol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-24-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-methyl-1H-pyrrol-2-yl)methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-25-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-
, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-26-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-amino-2-(1H-pyrrol-2-ylmethylene)-, (2Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-27-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4,5-dimethyl-1H-pyrrol-2-yl)methylene]-
(9CI) (CA INDEX NAME)



RN 312970-28-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-29-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-30-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-methyl-1H-pyrrol-2-yl)methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-31-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(4-hydroxybutyl)-1H-pyrrol-2-yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-32-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(2-hydroxyethyl)-1H-pyrrol-2-

yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-33-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[1-[3-(dimethylamino)propyl]-1H-pyrrol-2-
yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-34-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-bromo-1H-pyrrol-2-yl)methylene]-,
(2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-36-8 CAPLUS
CN 1H-Pyrrole-1-acetic acid,
2-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-
ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-37-9 CAPLUS
CN 1H-Pyrrole-1-acetamide, 2-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-38-0 CAPLUS
CN 1H-Pyrrole-1-acetamide, 2-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-39-1 CAPLUS
CN 1H-Pyrrole-1-acetamide, 2-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-40-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-41-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-chloro-2-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312970-42-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-7-methyl- (9CI) (CA INDEX NAME)



RN 312970-43-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-6-methyl- (9CI) (CA INDEX NAME)



RN 312970-44-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312970-45-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-7-methoxy- (9CI)
(CA INDEX NAME)



RN 312970-46-0 CAPLUS
CN Acetamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-6-yl]- (9CI) (CA INDEX NAME)



RN 312970-47-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-7-nitro- (9CI) (CA INDEX NAME)



RN 312970-48-2 CAPLUS
CN Acetamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-50-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-51-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[1-[(2-hydroxyethoxy)methyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-52-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-53-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-(1H-indol-3-ylmethylene)- (9CI)
(CA INDEX NAME)



RN 312970-54-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-amino-2-(1H-indol-3-ylmethylene)- (9CI)
(CA INDEX NAME)



RN 312970-55-1 CAPLUS
CN Urea,
N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 312970-56-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312970-57-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-methyl-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-58-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-[[6-[(2-hydroxyethoxy)methyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-59-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-methyl-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-60-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(1-methylethyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-61-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)-2-hydroxypropyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-62-0 CAPLUS
CN Benzamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-63-1 CAPLUS
CN Acetamide,
2-chloro-N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-64-2 CAPLUS
CN 4-Morpholineacetamide,
N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-65-3 CAPLUS
CN 2-Propenamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-66-4 CAPLUS
CN 4-Morpholinepropanamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-67-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-68-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312970-69-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-amino-2-methyl-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-70-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 312970-71-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 312970-72-2 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312970-73-3 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312970-74-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6,7,8,9-tetrahydro-8-(hydroxymethyl)pyrido[1,2-a]indol-10-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-75-5 CAPLUS
CN 1H-Indole-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 312970-76-6 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312970-77-7 CAPLUS
CN 1H-Indole-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-.alpha.-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 312970-78-8 CAPLUS
CN 1H-Indole-7-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312970-79-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 312970-80-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(1-cyclopentyl-1H-indol-3-yl)methylene]-
(9CI) (CA INDEX NAME)



RN 312970-81-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(tetrahydro-3-furanyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-82-4 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 312970-83-5 CAPLUS
CN Acetamide,
N-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 312970-84-6 CAPLUS
CN 1H-Indole-1-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 312970-85-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-(hydroxymethyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-86-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-87-9 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-88-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1-methyl-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 312970-89-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 3-(dimethylamino)propyl ester (9CI) (CA INDEX NAME)



RN 312970-90-4 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1-(2-hydroxyethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 312970-91-5 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312970-92-6 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312970-93-7 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 312970-94-8 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 312970-95-9 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312970-96-0 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312970-97-1 CAPLUS
CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 312970-98-2 CAPLUS
CN Piperazine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-6-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312970-99-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[5-[2-(1-piperidinyl)ethoxy]-1H-indol-3-yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312971-00-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[5-[3-(dimethylamino)propoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-01-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-02-1 CAPLUS
CN 1H-Indole-1-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-[3-(dimethylamino)propoxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 312971-03-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[3-(dimethylamino)propoxy]-1-methyl-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-04-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[1-methyl-5-[2-(4-morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-05-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-06-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[5-[2-(dimethylamino)ethoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-07-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[6-[3-(dimethylamino)propoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-08-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[6-[2-(4-morpholinyl)ethoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-09-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[6-[2-(1-piperidinyl)ethoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-10-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[6-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-11-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[6-[2-(dimethylamino)ethoxy]-1H-indol-3-
yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-12-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(dimethylamino)-2-methylpropoxy]-
1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-13-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-
1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-14-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[6-[(1-methyl-3-piperidinyl)methoxy]-1H-
indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-15-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[7-[(dimethylamino)methyl]-6-hydroxy-1H-
indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-16-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[7-[(dimethylamino)methyl]-6-[2-(4-
morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-17-8 CAPLUS
CN Urea, N-[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2-
methyl-1H-indol-5-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 312971-18-9 CAPLUS
CN Benzenesulfonamide, N-[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2-methyl-1H-indol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312971-19-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[[[3-(dimethylamino)propyl]amino]methyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-20-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[[(2-methoxyethyl)amino]methyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-21-4 CAPLUS
CN 1H-Indole-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312971-22-5 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312971-23-6 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 312971-24-7 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312971-25-8 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312971-26-9 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312971-27-0 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312971-28-1 CAPLUS
CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 312971-29-2 CAPLUS
CN 1H-Indole-1-acetamide, N,N-bis[2-(diethylamino)ethyl]-3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312971-30-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 312971-31-6 CAPLUS
CN 1H-Indole-1-acetamide,
N-[2-(diethylamino)ethyl]-3-[(3,4-dihydro-3-oxo-2H-
1,4-benzothiazin-2-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 312971-32-7 CAPLUS
CN 1H-Indole-7-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-
ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312971-33-8 CAPLUS
CN Piperazine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-
ylidene)methyl]-1H-indol-7-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312971-34-9 CAPLUS
CN 1-Piperazineethanol, 4-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-7-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 312971-35-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(4-hydroxybutyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-36-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-nitro-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312971-37-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312971-38-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-
(9CI) (CA INDEX NAME)



RN 312971-39-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[(2-hydroxyethoxy)methyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-40-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-41-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(4-morpholinyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-42-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-[3-(dimethylamino)propoxy]-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312971-43-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[4-(acetyloxy)butyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-44-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(2-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-45-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-46-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-47-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-48-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 312971-49-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312971-50-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312971-51-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)



RN 312971-52-1 CAPLUS
CN Piperazine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-pyrrolo[2,3-b]pyridin-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312971-53-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetamide, N-[2-(diethylamino)ethyl]-3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 312971-54-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 312971-55-4 CAPLUS
CN 1H-1,4-Diazepine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-pyrrolo[2,3-b]pyridin-1-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 312971-56-5 CAPLUS
CN Piperazine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-pyrrolo[2,3-b]pyridin-1-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 312971-57-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-pyrrolo[2,3-b]pyridin-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 312971-58-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-1-acetamide, N,N-bis[2-(diethylamino)ethyl]-3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 312971-59-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[7-(phenylmethoxy)-1H-pyrrolo[2,3-c]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-60-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6,7-dihydro-7-oxo-1H-pyrrolo[2,3-c]pyridin-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-61-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[1-[2-(dimethylamino)ethyl]-6,7-dihydro-
7-oxo-1H-pyrrolo[2,3-c]pyridin-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-62-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-imidazol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312971-63-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(trifluoromethyl)-1H-imidazol-2-yl]methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312971-64-5 CAPLUS
CN 1H-Imidazole-4-carbonitrile,
2-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-
2-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312971-65-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-methyl-1H-benzimidazol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-66-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-methyl-1H-imidazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-67-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312971-68-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(5-methyl-1H-imidazol-4-yl)methylene]-7-nitro- (9CI) (CA INDEX NAME)



RN 312971-69-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-amino-2-[(5-methyl-1H-imidazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-70-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-methyl-1H-imidazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-71-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-ethyl-5-methyl-1H-imidazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-72-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(diethylamino)ethyl]-5-methyl-1H-imidazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-73-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(diethylamino)ethyl]-4-methyl-1H-imidazol-5-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-74-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-methyl-1-[2-(4-morpholinyl)ethyl]-1H-imidazol-5-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-75-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-methyl-1-[2-(4-morpholinyl)ethyl]-1H-imidazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-76-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-methyl-2-(methylthio)-1H-imidazol-5-yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312971-77-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312971-78-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-hydroxy-1H-imidazol-4-yl)methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312971-79-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(3-furanylmethylene)- (9CI) (CA INDEX NAME)





RN 312971-80-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(3-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 312971-81-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-methyl-1H-pyrazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-82-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-phenyl-1H-pyrazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-83-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(diethylamino)ethyl]-3-methyl-1H-pyrazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-84-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(diethylamino)ethyl]-5-methyl-1H-pyrazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-85-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[3-methyl-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-86-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[5-methyl-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-87-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-methyl-1H-pyrazol-4-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312971-88-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(1,1-dimethylethyl)-1H-pyrazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312971-89-4 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 312971-90-7 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 312971-91-8 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 312971-92-9 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 312971-93-0 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 312971-94-1 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-3-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 312971-95-2 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 312971-96-3 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-3-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312971-97-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-

ylidene)methyl]-3-methyl-1H-pyrazol-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 312971-98-5 CAPLUS
CN 1H-Pyrazole-1-acetamide, N-[2-(diethylamino)ethyl]-4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 312971-99-6 CAPLUS
CN Piperazine, 1-[[4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-methyl-1H-pyrazol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312972-00-2 CAPLUS
CN Piperazine, 1-[[4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-3-methyl-1H-pyrazol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312972-01-3 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 312972-02-4 CAPLUS
CN 1-Piperazineethanol, 4-[[4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-methyl-1H-pyrazol-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 312972-03-5 CAPLUS
CN Piperazine, 1-[[4-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-methyl-1H-pyrazol-1-yl]acetyl]-4-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 312972-04-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312972-05-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-06-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indazol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-07-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-thiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-08-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrazol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-09-1 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 312972-10-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312972-11-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 312972-12-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 312972-13-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312972-14-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[2-(dimethylamino)-5-thiazolyl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-15-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-16-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-(4-morpholinylmethyl)-1H-indol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-17-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-7-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-18-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-[(dimethylamino)methyl]-1H-indol-7-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-19-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-(4-morpholinylmethyl)-1H-indol-7-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-20-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-(1-piperidinylmethyl)-1H-indol-7-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-21-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-[(4-methyl-1-piperazinyl)methyl]-1H-indol-7-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312972-79-5 CAPLUS
CN 2H-1,4-Benzothiazine-3(4H)-thione, 2-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-80-8 CAPLUS
CN 2H-1,4-Benzothiazine-3(4H)-thione, 2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 312972-85-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, oxime (9CI) (CA INDEX NAME)



RN 312972-86-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-
, oxime (9CI) (CA INDEX NAME)



RN 312972-87-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-,
O-acetyloxime
(9CI) (CA INDEX NAME)



RN 312972-88-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-,
O-benzoyloxime (9CI) (CA INDEX NAME)



RN 312972-91-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, 1,1-dioxide
(9CI) (CA INDEX NAME)



RN 312972-92-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-
, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312972-93-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312972-94-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-
, 1-oxide (9CI) (CA INDEX NAME)



RN 312972-95-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, 1-oxide (9CI) (CA INDEX NAME)



RN 312972-96-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-methoxyphenyl)amino]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312972-97-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-methylphenyl)amino]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312972-98-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[[4-(dimethylamino)phenyl]amino]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312972-99-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(phenylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312973-00-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-chlorophenyl)amino]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)





RN 312973-01-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1H-pyrazol-3-ylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312973-02-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1H-1,2,4-triazol-3-ylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312973-03-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1H-indazol-5-ylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312973-04-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-pyridinylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)





RN 312973-05-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1H-indol-5-ylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312973-46-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-47-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-methoxy-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-48-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrol-2-ylmethylene)-6-(trifluoromethoxy)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-49-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-methyl-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-51-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-chloro-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-52-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-53-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-methyl-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-54-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-(1H-pyrrol-2-ylmethylene)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-55-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-methyl-1H-pyrrol-2-yl)methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-56-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **312973-57-2P 312973-58-3P 312973-59-4P**
312973-60-7P 312973-61-8P 312973-62-9P
312973-63-0P 312973-64-1P 312973-65-2P
312974-25-7P 312974-26-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)

RN 312973-57-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(E)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-58-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]methylene]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 312970-52-8
CMF C22 H23 N3 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 312973-59-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 312971-38-3
CMF C16 H11 N3 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 312973-60-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[(2-hydroxyethoxy)methyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 312971-39-4
CMF C19 H17 N3 O3 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 312973-61-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 312971-40-7
CMF C21 H22 N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 312973-62-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[2-(4-morpholinyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 312971-41-8
CMF C22 H22 N4 O2 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 312973-63-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 7-[3-(dimethylamino)propoxy]-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 312971-42-9
CMF C21 H22 N4 O2 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 312973-64-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(trifluoromethyl)-1H-imidazol-2-yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 312973-65-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-2-ylmethylene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312974-25-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 312974-26-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-hydroxy-1H-indol-3-yl)methylene]-(9CI) (CA INDEX NAME)



IT **70685-26-6 312973-44-7 312973-45-8**
RL: RCT (Reactant)
(prepn. and effects of benzothiazinones and benzoxazinones as protein

kinase inhibitors)
RN 70685-26-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(dimethylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312973-44-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 312973-45-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-hydroxy-1H-indol-3-yl)methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 2 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:756696 CAPLUS
DOCUMENT NUMBER: 133:321892
TITLE: Preparation of hydroxamic acid derivatives as matrix metallo-proteinase inhibitors
INVENTOR(S): Scarlato, Gerard Robert; Hadida, Ruah Sara Sabina; Nishimura, Tamiki; Nakatsuka, Masashi; Samizo, Fumio; Kamikawa, Yumiko; Houtigai, Hitoshi

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan; Hadida Ruah, Sara Sabina
SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063197	A1	20001026	WO 2000-US10383	20000419

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-129933 P 19990419
OTHER SOURCE(S): MARPAT 133:321892
GI



I



II

AB The title compds. [I; X = (un)substituted alkylene, ortho-heteroarylene; Y1 = O, S, SO, SO2; Y2 = O, S; one of R1 and R3 = (CHR4)nCR5R6CONHOH; the other R1 and R3 = H, (un)substituted alkyl, cycloalkyl; R2 = H, (un)substituted alkyl, alkenyl, etc.; R4-R6 = H, (un)substituted alkyl, alkenyl, etc.; or R5 may be joined with R4 or R6 to form, with the carbon atom which they attach (un)substituted cycloalkane or heterocycloalkane; n = 0-4], useful as matrix metallo-proteinase (e.g., MMP-2, MMP-3, MMP-9, and MMP-13) inhibitors, were prepd. E.g., a multi-step synthesis of 1,4-benzothiazin-3(4H)-one II which showed IC50 of 1.0 .mu.M against MMP-2, and 20% inhibition of TNF-.alpha. prodn. at 5 .mu.M, was given.

IT **55043-26-0**
RL: RCT (Reactant)
(prepn. of hydroxamic acid derivs. as matrix metallo-proteinase inhibitors)

RN 55043-26-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **302836-56-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of hydroxamic acid derivs. as matrix metallo-proteinase inhibitors)
RN 302836-56-2 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid, 3,4-dihydro-3-oxo-2-[(4-phenoxyphenyl)methylene]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5
REFERENCE(S): (1) Ciba Geigy Ag; EP 0606046 A 1994 CAPLUS
(2) Du Pont Merck Pharma; WO 9633176 A 1996 CAPLUS
(3) Hoechst Ag; DE 19542189 A 1997 CAPLUS
(4) Sunkyong Ind Ltd; WO 9620936 A 1996 CAPLUS
(5) Yoshitomi Pharmaceutical; FR 2434150 A 1980 CAPLUS

L14 ANSWER 3 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:665626 CAPLUS
DOCUMENT NUMBER: 133:253885
TITLE: Thiazine-indigo compounds, their production and use and intermediates therefor
INVENTOR(S): Borchert, Till; Kaul, Bansi Lal; Piastra, Bruno; Wolf, Valerie; Rothe, Petra; Unverdorben, Leonhard
PATENT ASSIGNEE(S): Clariant Finance (BVI) Limited, Virgin I. (Brit.)
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1036821	A1	20000920	EP 2000-810221	20000316

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO
JP 2000344757 A2 20001212 JP 2000-58620 20000303
PRIORITY APPLN. INFO.: GB 1999-6120 A 19990318
GB 1999-18805 A 19990811
OTHER SOURCE(S): MARPAT 133:253885
AB New heterocyclic compds. are disclosed which are used as intermediates for the prepn. of trans-thiazine-indigo pigments which are in part new compds. and can be used for the mass pigmentation of org. substrates. Also disclosed are different environmentally friendly water-based processes for the prepn. of the new heterocyclic compds. and the corresponding pigments. Thus, o-aminothiophneol was cyclocondensed with 2,3-dichloromaleic acid to give a benzothiazine deriv. which was then cyclocondensed with bis(4-carboxamido-2-nitrophenyl) disulfide to provide cis-thiazine-indigo compd. which was isomerized to the trans red-orange pigment.
IT **106660-05-3P 294867-02-0P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation)
(intermediate; prodn. of thiazine-indigo pigments)
RN 106660-05-3 CAPLUS
CN Acetic acid, chloro(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 294867-02-0 CAPLUS
CN Acetic acid, chloro(7-chloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4
REFERENCE(S):
(1) Basf Ag; DE 2536120 A 1977 CAPLUS
(2) Kaul, B; US 3803139 A 1974 CAPLUS
(3) Kaul, B; WO 9832800 A 1998 CAPLUS
(4) Kaul, B; HELVETICA CHIMICA ACTA 1974, V57(8), P2664 CAPLUS

L14 ANSWER 4 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:616053 CAPLUS
DOCUMENT NUMBER: 134:193369

TITLE: Synthesis and structural study of substituted arylideneimidazolidines and arylidenebenzothiazines

AUTHOR(S): Brandao, S. S. F.; Guarda, V. L.; Pitta, I. R.; Chantegrel, J.; Perrissin, M.; Souza, V. M.; Galdino, S. L.; Thomasson, F.; Lima, M. C. A.; Leite, L. F. C. C.; Luu-Duc, C.

CORPORATE SOURCE: Universidade Federal de Pernambuco, Recife, 50.670-901, Brazil

SOURCE: Boll. Chim. Farm. (2000), 139(2), 54-58
CODEN: BCFAAI; ISSN: 0006-6648

PUBLISHER: Societa Editoriale Farmaceutica

DOCUMENT TYPE: Journal

LANGUAGE: French

AB Synthesis and physicochem. properties of six 5-arylidene-3-benzyl-1-methyl-2-thioxoimidazolidin-4-ones and three 2-arylidene-6-nitro-2H-1,4-benzothiazin-3(4H)-ones have been described. These new compds. were synthesized by the Knoevenagel condensation reaction from arom. aldehydes.

The N-alkylation reaction of arylidenebenzothiazines by Me iodide gives the N-methylarylidenebenzothiazines.

IT **328001-00-9P 328001-01-0P 328001-02-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and structural study of arylideneimidazolidines and arylidenebenzothiazines)

RN 328001-00-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]-6-nitro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 328001-01-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-bromophenyl)methylene]-6-nitro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 328001-02-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-fluorophenyl)methylene]-6-nitro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **328001-03-2P 328001-04-3P 328001-05-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and structural study of arylideneimidazolidines and arylidenebenzothiazines)
RN 328001-03-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]-4-methyl-6-nitro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 328001-04-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-bromophenyl)methylene]-4-methyl-6-nitro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 328001-05-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-fluorophenyl)methylene]-4-methyl-6-nitro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 15
REFERENCE(S):
(1) Albuquerque, J; Ann Pharm Fr 1995, V53, P209 CAPLUS
(2) Albuquerque, J; Pharmazie 1995, V50, P387 CAPLUS
(4) Costa, D; J Pharm Belg 1995, V50, P5 CAPLUS
(5) Del Corona, L; Eur J Med Chem 1992, V27, P419 CAPLUS
(7) Grandolini, G; Eur J Med Chem 1986, V21, P455 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:487539 CAPLUS
DOCUMENT NUMBER: 131:129999
TITLE: Preparation of oxazolidines substituted with bicycles as antimicrobial agents
INVENTOR(S): Bartel, Stephan; Guarnieri, Walter; Haebich, Dieter; Raddatz, Siegfried; Riedl, Bernd; Rosentreter, Ulrich; Ruppelt, Martin; Stolle, Andreas; Wild, Hanno; Endermann, Rainer; Kroll, Hein-Peter
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 88 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19802239	A1	19990729	DE 1998-19802239	19980122
WO 9937641	A1	19990729	WO 1999-EP96	19990109
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926161	A1	19990809	AU 1999-26161	19990109
EP 1049692	A1	20001108	EP 1999-906112	19990109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: DE 1998-19802239 A 19980122
WO 1999-EP96 W 19990109

OTHER SOURCE(S): MARPAT 131:129999
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R = Me, Et, COOMe, (CH3)2CH, R1 = H; R-R1 = (CH2)3; R3 =
OH, OSO2Me, N3, NH2, NHCONH2, NHAc, NHCOCH2Br, NHCOOMe, NHCOEt, NHCOCF3, NHCOOBu-t, cyclopropylcarbonylamino, 2-furylcarbonylamino, NHP(OMe)2:O, etc.; X = C:O, CH2, S, S:O, SO2; Y = CH2, CHCH3, NMe, C:O, C6H5CH:C, C6H5CH2C:, 4-ClC6H4CH:C, 4-MeOC6H4CH:C, etc.; Z = O, CH2], enantiomers, and salts are prepd. Thus, the title compd. II was prepd. from 7-nitro-2H-1,4-benzoxazin-3-one, C6H5CH2OCONHCl, and (R)-(-)-glycidyl butyrate via redn. cyclization and was tested against Staphylococcus aureus, Mycobacterium smegmatis, and Streptococcus pneumoniae.

IT **233775-06-9P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of oxazolidines substituted with bicycles as antimicrobial agents)

RN 233775-06-9 CAPLUS

CN Acetamide, N-[[(5S)-3-[3,4-dihydro-4-methyl-3-oxo-2-(phenylmethylene)-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.





IT **233775-07-0P 233775-08-1P 233775-09-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of oxazolidines substituted with bicycles as antimicrobial agents)
RN 233775-07-0 CAPLUS
CN Acetamide,
N-[[(5S)-3-[2-[(4-chlorophenyl)methylene]-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 233775-08-1 CAPLUS
CN Acetamide,
N-[[(5S)-3-[3,4-dihydro-2-[(4-methoxyphenyl)methylene]-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 233775-09-2 CAPLUS
CN Acetamide,
N-[[(5S)-3-[3,4-dihydro-4-methyl-3-oxo-2-(4-pyridinylmethylene)-2H-1,4-benzothiazin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L14 ANSWER 6 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:284060 CAPLUS
DOCUMENT NUMBER: 131:44782
TITLE: Synthesis of 2-substituted 6,8-dichloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazine 1,1-dioxides and 1-oxides as glycine-NMDA receptor antagonists
AUTHOR(S): Varano, Flavia; Catarzi, Daniela; Colotta, Vittoria; Filacchioni, Guido; Cecchi, Lucia; Galli, Alessandro; Costagli, Chiara
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Firenze, Florence, 50121, Italy
SOURCE: Farmaco (1998), 53(12), 752-757
CODEN: FRMCE8; ISSN: 0014-827X
PUBLISHER: Elsevier Science S.A.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Title compds. I (R = H, Br), II (R = H, Br), and the corresponding monoxides, bioisosteres of RPR 104632, in which the 3-carboxylic group was replaced by a carbonyl group, were synthesized. Comparative in vitro pharmacol. studies on this series of RPR 104632 analogs were performed using receptor binding assays. None of these compds. showed detectable binding affinity for the glycine-NMDA receptor.

IT **227012-79-5P 227012-80-8P 227012-81-9P**
227012-82-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and lack of affinity for glycine-NMDA receptor)

RN 227012-79-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6,8-dichloro-2-(phenylmethylene)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 227012-80-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(3-bromophenyl)methylene]-6,8-dichloro-,
1,1-dioxide (9CI) (CA INDEX NAME)



RN 227012-81-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6,8-dichloro-2-(phenylmethylene)-, 1-oxide (9CI) (CA INDEX NAME)



RN 227012-82-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(3-bromophenyl)methylene]-6,8-dichloro-,
1-oxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14
REFERENCE(S): (1) Boireau, A; Eur J Pharmacol 1996, V300, P237 CAPLUS
(4) de Lean, A; Am J Physiol 1978, V235, PE97 CAPLUS
(7) Johnson, J; Nature 1987, V325, P529 CAPLUS
(8) Kemp, J; Trends Pharmacol Sci 1993, V14, P20 CAPLUS
(9) Kulagowski, J; Exp Opin Ther Patents 1996, V6, P1069 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:248133 CAPLUS
DOCUMENT NUMBER: 129:4618
TITLE: Pummerer reaction of 2-vinylcyclopropyl sulfoxides: generation and reactions of butadienylthionium ion intermediates
AUTHOR(S): Iwama, Tetsuo; Matsumoto, Harutoshi; Shimizu, Hiroshi; Kataoka, Tadashi; Muraoka, Osamu; Tanabe, Genzoh
CORPORATE SOURCE: Gifu Pharmaceutical University, Gifu, 502-8585, Japan
SOURCE: J. Chem. Soc., Perkin Trans. 1 (1998), (9), 1569-1576
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:4618

AB Generation of butadienylthionium ions in the Pummerer reactions of 2-vinylcyclopropyl sulfoxides was studied. Although the Pummerer reaction of 2-vinylcyclopropyl sulfoxides are complicated, benzothiazinone derivs. smoothly react with trifluoroacetic anhydride to give 1,3-dienes in good yields. The reactions proceed via butadienylthionium ions by proton abstraction from the 2'-Me group or the cyclopropane ring. Reactions of disubstituted benzothiazinones provided cyclic dienes while treatment of mono- or unsubstituted derivs. gave acyclic conjugated dienes. Vinylcyclopropyl sulfoxides were prepd. by MCPBA oxidn. of the corresponding 2-vinylcyclopropyl sulfides, resp., which were obtained by cyclopropanation of .alpha.-chloro sulfides with 1,3-dienes via a 5,6-dihydro-2H-thiopyranium intermediate.

IT **207507-89-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(Pummerer reaction of vinylcyclopropyl sulfoxides and generation and reaction of butadienylthionium intermediates)

RN 207507-89-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2Z)-4-hydroxy-2-phenyl-2-butenylidene]-4-methyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





IT **207506-88-5P 207506-89-6P 207506-90-9P**
207506-91-0P 207506-92-1P 207506-93-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 207506-88-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2E)-4-hydroxy-2-butenylidene]-4-methyl-
, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 207506-89-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2E)-4-(acetyloxy)-2-butenylidene]-4-
methyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 207506-90-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2E)-4-hydroxy-2-methyl-2-butenylidene]-

4-methyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 207506-91-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2Z)-4-hydroxy-2-methyl-2-butenylidene]-
4-methyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 207506-92-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2E)-4-hydroxy-3-methyl-2-butenylidene]-
4-methyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 207506-93-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(2E)-4-hydroxy-2-phenyl-2-butenylidene]-
4-methyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 8 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:261364 CAPLUS
DOCUMENT NUMBER: 126:343367
TITLE: Acid-promoted isomerization of 1-acceptor-1-sulfenyl-substituted 2-vinylcyclopropanes with C1-C2 bond fission and novel 1,5-sulfenyl rearrangement
AUTHOR(S): Iwama, Tetsuo; Matsumoto, Harutoshi; Kataoka, Tadashi
CORPORATE SOURCE: Gifu Pharmaceutical University, Gifu, 502, Japan
SOURCE: J. Chem. Soc., Perkin Trans. 1 (1997), (6), 835-843
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 126:343367
GI





AB The 1-acceptor-1-sulfenyl-substituted vinylcyclopropane derivs., i.e., (ethenyl)(mercapto)cyclopropane derivs., I [R1 = (un)substituted Ph, Me; R2 = H, Me; R3 = CO2Me, cyano] underwent C1-C2 bond fission and 1,5-sulfenyl rearrangement to give 6-sulfenyl-.alpha.,.beta.;.gamma.,.delta.-unsatd. carboxylic esters and nitriles II (same R1-R3). by treatment with acid. The reactions proceed smoothly by use of a sulfonic acid such as p-TsOH.cntdot.H2O, CF3SO3H etc. in a

non-polar solvent. The result obtained from reactions of III implied that the C1-C2 bond cleavage and deprotonation from the C2-Me group of substrates 1 occur via a concerted process. A cross-over expt. showed that the 1,5-sulfenyl shift proceeded intermolecularly. Addn. of a catalytic amt. of m-MeC6H4SH improves the yield of the rearranged product II.

IT **190005-72-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 190005-72-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2,3-dimethyl-2-butenylidene)-4-methyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 9 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:885820 CAPLUS

DOCUMENT NUMBER: 124:55745

TITLE: Study of microwave irradiation effect on condensation of 6-R-3-formylchromones with active methylene compounds

AUTHOR(S): Gasparova, Renata; Lacova, Margita

CORPORATE SOURCE: Dep. Org. Chem., Comenius Univ., Bratislava, 842 15, Slovakia

SOURCE: Collect. Czech. Chem. Commun. (1995), 60(7), 1178-85
CODEN: CCCCAK; ISSN: 0010-0765

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:55745

AB Condensation of 6-R-3-formylchromones with 3,3-dimethyl-1,3-cyclohexanedione, 1,3-indandione, 1,2'-biindenylidene-3,1',3'-trione (bindone), 2-oxo-1,4-benzothiazine, and 3-oxo-2,3-dihydro-1-thia-3a,8-diazacyclopent[a]indene by the "classical" method, as well as condensation in a microwave oven, has been studied. Some subsequent reactions of these products are described.

IT **172170-67-1P 172170-70-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(study of microwave irradn. effect on condensation of formylchromones with active methylene compds.)

RN 172170-67-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-oxo-4H-1-benzopyran-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 172170-70-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6-chloro-4-oxo-4H-1-benzopyran-3-yl)methylene]- (9CI) (CA INDEX NAME)



IT **172170-68-2P 172170-69-3P 172170-72-8P**
172170-73-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(study of microwave irradn. effect on condensation of formylchromones with active methylene compds.)
RN 172170-68-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6-methyl-4-oxo-4H-1-benzopyran-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 172170-69-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-(acetyloxy)-4-oxo-4H-1-benzopyran-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 172170-72-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-(2-hydroxyphenyl)-1H-pyrazol-4-yl]methylene]- (9CI) (CA INDEX NAME)



RN 172170-73-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[3-(5-chloro-2-hydroxyphenyl)-1H-pyrazol-
4-yl]methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 10 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:784965 CAPLUS
DOCUMENT NUMBER: 123:198818
TITLE: Preparation and formulation of benzothiazine derivatives as antioxidants
INVENTOR(S): Kawashima, Yoichi; Ota, Atsutoshi; Mibu, Hiroyuki; Matsubayashi, Kenichiro
PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9513269 DS	A1	19950518	WO 1994-JP1907	19941110
W: CA, CN, FI, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 07138241	A2	19950530	JP 1993-283684	19931112
JP 2840807	B2	19981224		
JP 07138242	A2	19950530	JP 1993-283685	19931112
JP 2840808	B2	19981224		

PRIORITY APPLN. INFO.: JP 1993-283684 19931112
JP 1993-283685 19931112
OTHER SOURCE(S): MARPAT 123:198818
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 represents optionally protected hydroxy; R2 represents lower alkyl; R3 represents hydrogen, lower alkyl, optionally protected hydroxy or lower alkoxy, wherein the lower alkyl group may be substituted by optionally protected hydroxy, amino or lower alkylamino; R4 represents carboxyl which may be in the form of an ester or amide; A represents alkylene; and B represents CH2, etc.] are prepd. I stabilize proteins, inhibit lipid peroxide formation, and are useful as potential agents for the treatment of cataract. The title compds. II and III (prepn. given) in vitro at 10-6 M gave 99% inhibition of lipid peroxidn.

IT **156776-32-8**
RL: RCT (Reactant)
(prepn. of benzothiazine derivs. as antioxidants)

RN 156776-32-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]- (9CI) (CA INDEX NAME)



IT **167549-24-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of benzothiazine derivs. as antioxidants)

RN 167549-24-8 CAPLUS

CN 2H-1,4-Benzothiazine-3(4H)-thione, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 11 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:761702 CAPLUS

DOCUMENT NUMBER: 123:169638

TITLE: Preparation of 3-oxo-1,4-benzothiazines as protein stabilizers and lipid peroxide formation inhibitors

INVENTOR(S): Kawashima, Yoichi; Ota, Atsuigaoka; Morikawa, Yuko; Mibu, Hiroyuki

PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 657444	A1	19950614	EP 1994-119182	19941205	
EP 657444	B1	19990331			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
US 5547952	A	19960820	US 1994-347043	19941130	
JP 07215953	A2	19950815	JP 1994-300907	19941205	
JP 2964380	B2	19991018			
AT 178323	E	19990415	AT 1994-119182	19941205	
CA 2137626	AA	19950610	CA 1994-2137626	19941208	
FI 9405762	A	19950610	FI 1994-5762	19941208	
NO 9404762	A	19950612	NO 1994-4762	19941208	
CN 1109882	A	19951011	CN 1994-112918	19941208	

PRIORITY APPLN. INFO.: JP 1993-309131 19931209
OTHER SOURCE(S): MARPAT 123:169638
GI



I



II

AB Tile compds. [I; R1 = (protected) hydroxy; R2 = alkyl; R3 = H, OH, alkyl, alkoxy, etc.; R4 = tetrazolyl, alkoxysulfonyl, dialkoxysulfinyl, etc.; Z = alkylene] were prepd. Thus, title compd. II (R = H) was N-alkylated with ClCH2OMe and the product treated successively with Me3SiI and (EtO)3P to give, after sapon., II [R = CH2P(O)(OH)2] which gave 98.8 and 100% inhibition of bovine serum denaturation and lipid peroxide formation in vitro at 10-4 and 10-5M, resp.

IT **156776-32-8**
RL: RCT (Reactant)
(prepn. of 3-oxo-1,4-benzothiazines as protein stabilizers and lipid peroxide formation inhibitors)

RN 156776-32-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:517831 CAPLUS

DOCUMENT NUMBER: 123:83330
TITLE: Generation and reactions of butadienylthionium ions from 2-vinylcyclopropyl sulfoxides under Pummerer conditions
AUTHOR(S): Kataoka, Tadashi; Matsumoto, Harutoshi; Iwama, Tetsuo; Ito, Taizo; Shimizu, Hiroshi
CORPORATE SOURCE: Gifu Pharmaceutical University, Gifu, 502, Japan
SOURCE: J. Chem. Soc., Perkin Trans. 1 (1995), (7), 737-9
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:83330

AB Treatment of 2-vinylcyclopropyl sulfoxides lacking an .alpha.-hydrogen with acid anhydrides produced butadienylthionium ion intermediates to give cyclic or acyclic conjugated dienes.

IT **165333-87-9P 165333-88-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(Pummerer reaction of vinylcyclopropyl sulfoxides)

RN 165333-87-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(4-hydroxy-2-methyl-2-butenylidene)-4-methyl-, (?,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 165333-88-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[4-(acetyloxy)-2-butenylidene]-4-methyl-, (?,E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



IT **165333-84-6P 165333-85-7P 165333-86-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 165333-84-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(4-hydroxy-2-butenylidene)-4-methyl-, (?,E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 165333-85-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(4-hydroxy-3-methyl-2-butenylidene)-4-methyl-, (?,E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 165333-86-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(4-hydroxy-2-methyl-2-butenylidene)-4-methyl-, (?,E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



L14 ANSWER 13 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:508814 CAPLUS
DOCUMENT NUMBER: 121:108814
TITLE: Preparation of 3-oxo-1,4-benzothiazine derivatives having protein stabilization activity and inhibiting formation of lipid peroxide
INVENTOR(S): Kawashima, Yoichi; Ota, Atsutoshi; Mibu, Hiroyuki
PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9405647	A1	19940317	WO 1993-JP1190	19930825
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 627425	A1	19941207	EP 1993-919568	19930825
EP 627425	B1	20001102		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

JP 2829442	B2	19981125	JP 1993-507042		19930825
AT 197297	E	20001115	AT 1993-919568		19930825
US 5496817	A	19960305	US 1994-211940		19940422
PRIORITY APPLN. INFO.:			JP 1992-231669	A	19920831
			WO 1993-JP1190	W	19930825

OTHER SOURCE(S): MARPAT 121:108814

GI



I



II

AB Compds. represented by general formula [I; R1 = (un)protected hydroxy; R2 = lower alkyl; R3 = H, lower alkyl, (un)protected hydroxy, lower alkoxy, provided that the lower alkyl may be substituted by (un)protected hydroxy, amino or lower alkylamino; R4 = carboxyl which may be in the form of ester or carboxamide; A = alkylene], which sre useful for the treatment of cataract, are prepd. Thus, BuLi in hexane was added dropwise with stirring to a soln. of (hydroxybenzylidene)dihydrobenzothiazine deriv. (II; R = H) in THF under NaCl-ice cooling followed by adding dropwise a soln. of BrCH2CO2Et in THF and the resulting mixt. was stirred at room temp. overnight to give 58.1% II (R = CH2CO2Et) which was sapond. with LiOH.H2O in MeOH and THF to give, after acidification with 6N HCl, 65.2% II (R = CH2CO2H)(III). III and II [R = (CH2)3CO2H] in vitro inhibited 81.2 and 99.1%, resp., formation of lipid peroxides when rat liver microsome was incubated with ADP, Fe2+, and ascorbic acid in 0.04 M Tris buffer contg. 0.09 M KCl.

IT **156776-32-8**
RL: RCT (Reactant)
(alkylation of, by Et bromoacetate)

RN 156776-32-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]- (9CI) (CA INDEX NAME)



IT **156776-25-9P 156776-26-0P 156776-27-1P**
156776-28-2P 156776-29-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for benzylideneoxobenzothiazine deriv. with protein stabilization and lipid peroxide formation-inhibiting activity)

RN 156776-25-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(acetyloxy)-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 156776-26-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(acetyloxy)-3-(1,1-dimethylethyl)phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 156776-27-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(acetyloxy)-3-methoxy-5-methylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 156776-28-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-[(dimethylamino)methyl]-5-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 156776-29-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 14 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:483354 CAPLUS
DOCUMENT NUMBER: 121:83354
TITLE: Preparation of 1,4-benzothiazine derivatives as lipoperoxide formation inhibitors
INVENTOR(S): Kawashima, Yoichi; Oota, Atsutoshi; Mibu, Hiroyuki
PATENT ASSIGNEE(S): Santen Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06073033	A2	19940315	JP 1992-231668	19920831
JP 2840800	B2	19981224		

OTHER SOURCE(S): MARPAT 121:83354
GI



I



II

AB The title derivs. I [R1 = (protected) OH; R2 = acyl, AR3; R3 = OH, lower alkoxy, amino, lower alkylamino, tetrahydropyranyloxy; A = lower alkylene]
or their salts, and their intermediates II or their salts are prepd. A soln. of (Me2CH)2NH in THF was treated dropwise with a soln. of BuLi in n-hexane at 0-10.degree., stirred for 20 min, treated dropwise with a soln. of 3,4-dihydro-4-[3-(N,N-dimethylamino)propyl]-3-oxo-2H-1,4-benzothiazine·in THF under ice cooling, stirred for 30 min, then treated with a soln. of 3,5-di-tert-butyl-4-hydroxybenzaldehyde in THF at room temp. overnight to give 38.8% erythro- and 28.9% threo-II [R1 = OH, R2 = (CH2)3NMe2] (III). A mixt. of erythro-III and Et3N in CH2Cl2 was treated

with MeSO2Cl under ice cooling to give 29.5% (Z)-I [R1 = OH, R2 = (CH2)3NMe2] (IV). IV at 10-6 M 98.8% inhibited the formation of lipoperoxides from ascorbic acid, ADP, Fe2+, and rats' liver microsome in 0.04 M tris buffer.

IT **126981-72-4P**, (Z)-2-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as lipoperoxide formation inhibitor)

RN 126981-72-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



Same as previous

L14 ANSWER 15 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:483237 CAPLUS
DOCUMENT NUMBER: 121:83237
TITLE: Stereoselective synthesis of 2-acyl-3,4-dihydro-1,4-benzothiazines
AUTHOR(S): Florio, Saverio; Epifani, Erbana; Ronzini, Ludovico; Fava, Giovanna Gasparri; Pelosi, Giorgio; Lucchini, Vittorio
CORPORATE SOURCE: Cent. Studio Strutturistica Diffrattometrica, Univ. Parma, Parma, Italy
SOURCE: Tetrahedron (1994), 50(17), 5037-48
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:83237
GI



I

AB 2-Benzylidene-4-methyl-3-oxo-2H-1,4-benzothiazine undergoes 1,2-addn. with
MeMgI and allylic magnesium halides to give 2-acyl-4-methyl-3-phenyl-3,4-dihydro-2H-1,4-benzothiazines I (R = Ac, CH2:CHCH2, CH2:CMeCH2, CH2:CHCHMe, R1 = H). Lithiation of I (R = Ac, R1 = H) and subsequent reaction with MeI and PhCH2Br leads to I (R = Ac, COEt, R1 = Me; R = COCHMe2, R1 = Me; R = Ac, R1 = CH2Ph). In contrast, the reaction of

lithiated I (R = Ac, R1 = H) with benzaldehyde and 2,6-dichlorobenzaldehyde furnished compds. I (R = COCH:CHPh, COCH:CHC6H3Cl2-2,6, R1 = H). The crystal structure of I (R = Ac, R1 = H) was detd.

IT **55043-21-5**
RL: RCT (Reactant)
(reaction of, with Grignard reagents)

RN 55043-21-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 16 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:483138 CAPLUS

DOCUMENT NUMBER: 121:83138

TITLE: Synthesis of lactams with potential cardiotonic activity

AUTHOR(S): Andreani, A.; Rambaldi, M.; Locatelli, A.; Leoni, A.; Bossa, R.; Chiericozzi, M.; Galatulas, I.; Salvatore, G.

CORPORATE SOURCE: Dip. Sci. Farm., Univ. Bologna, Bologna, 40126, Italy

SOURCE: Eur. J. Med. Chem. (1993), 28(10), 825-9
CODEN: EJMCA5; ISSN: 0223-5234

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB Twelve title compds., e.g., I, were prepd. and tested in spontaneously beating guinea-pig atria. I was the most potent inotropic agent.

IT **154617-53-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and cardiotonic activity of)

RN 154617-53-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2,5-dimethoxyphenyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 17 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:463033 CAPLUS
DOCUMENT NUMBER: 119:63033
TITLE: Potent antitumor agents with low toxicity
INVENTOR(S): Sakuta, Masayoshi; Yoneda, Toshuki; Nishimura, Michuki; Shiraishi, Tadayoshi
PATENT ASSIGNEE(S): Kanegafuchi Chemical Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05058894	A2	19930309	JP 1991-215448	19910827

OTHER SOURCE(S): MARPAT 119:63033
AB The antitumor agents are tyrosine kinase-activating 3,5-diisopropylbenzylidene heterocyclic compds., 4-thiazolinone derivs., 3,5-diisopropyl-4-hydroxystyrene derivs., 3,5-di-tert-butyl-4-hydroxystyrene derivs., .alpha.-cyanoacrylic acid amide derivs., .alpha.-benzylidene-.gamma.-butyrolactone or .gamma.-butyrolactam derivs., styrene derivs., 4-alkoxystyrene derivs., 3-phenylthiomethylstyrene derivs., tribenzylamine derivs., .alpha.-cyanocinnamic acid amide derivs. and salts thereof. Antitumor pharmacol. data are included.
IT **108402-28-4**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibitor)
RN 108402-28-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-hydroxy-3,5-bis(1-methylethyl)phenyl]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



L14 ANSWER 18 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:551006 CAPLUS

DOCUMENT NUMBER: 117:151006
TITLE: 1,4-benzothiazine-2-acetic acid derivatives, processes for production thereof and their use
INVENTOR(S): Aotsuka, Tomoji; Hosono, Hiroshi; Kurihara, Toshio; Nakamura, Yoshiyuki; Matsui, Tetsuo; Kobayashi, Fujio
PATENT ASSIGNEE(S): Sapporo Breweries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 71 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 492667	A1	19920701	EP 1991-122330	19911227
EP 492667	B1	19960417		
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 05092961	A2	19930416	JP 1991-354323	19911220
JP 2729430	B2	19980318		
CA 2058398	AA	19920628	CA 1991-2058398	19911223
AU 9190045	A1	19920709	AU 1991-90045	19911224
AU 634109	B2	19930211		
US 5252571	A	19931012	US 1991-813182	19911224
ES 2085950	T3	19960616	ES 1991-122330	19911227

PRIORITY APPLN. INFO.: JP 1990-415316 19901227
JP 1991-219346 19910806
OTHER SOURCE(S): MARPAT 117:151006
GI



I

AB Benzothiazineacetic acid derivs. I (R = H, alkyl; R1 = optionally-substituted benzyl or 5-benzothiazolylmethyl group, R2, R3 = H, halo, alkyl, alkoxy, alkylthio, CF3, CF3O; Z = O, S) and the related benzothiazolinylideneacetic acid derivs. and pharmaceutically-acceptable salts were prepd. Thus, alkylation of Et 2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-yl)acetate with 2-(bromomethyl)-5-fluorobenzothiazole in DMF afforded I (R = Et, R1 = 5-fluorobenzothiazolylmethyl, R2 = R3 = H, Z = O). The claimed compds. are aldose reductase inhibitors and are useful for the treatment of complications assocd. with diabetes.

IT **37893-72-4**
RL: RCT (Reactant)
(benzylation of)

RN 37893-72-4 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 19 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:423934 CAPLUS
DOCUMENT NUMBER: 113:23934
TITLE: Preparation of 1,4-benzothiazin-3(4H)-one derivatives,
useful as drugs, pesticides, and their intermediates
INVENTOR(S): Muehlstaedt, Manfred; Franke, Heike; Roemisch, Ines
PATENT ASSIGNEE(S): Karl-Marx-Universitaet Leipzig, Ger. Dem. Rep.
SOURCE: Ger. (East), 4 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 274220	A1	19891213	DD 1988-318270	19880725
DD 274220	B1	19930121		

GI



AB Three title derivs. I (R1 = Me, R2 = R3 = H; R1 = R2 = H, R3 = Ph, p-MeOC6H4) with the cited uses (no data) were prepd. by reaction of bis[(.alpha.,.beta.-unsatd. carbonylamino)phenyl] disulfides II with Cl(g) in a nonpolar solvent such as CH2Cl2 at -40.degree., followed by warming to room temp. and 4 h addnl. stirring. Thus, 0.01 mol II (R1 = R2 = H, R3 = Ph) in 100 mL CH2Cl2 was treated with a stream of Cl(g) for 25 min as above and worked up by crystn. (2 crops) to give 90.3% I (R1 = R2 = H, R3 = Ph).

IT **122686-63-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by cyclization of bis[(cinnamoylamino)phenyl] disulfide deriv.)

RN 122686-63-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[chloro(4-methoxyphenyl)methylene]- (9CI)
(CA INDEX NAME)



L14 ANSWER 20 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:216950 CAPLUS
DOCUMENT NUMBER: 112:216950
TITLE: Preparation of 3-oxo-1,4-benzothiazine derivatives for
removal of active oxygen species and for inhibition of
lipid peroxide formation
INVENTOR(S): Morita, Takakazu; Iso, Tadashi; Mita, Shiro; Kawashima, Yoichi
PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01287077	A2	19891117	JP 1988-117683	19880514
JP 07030058	B4	19950405		

OTHER SOURCE(S): MARPAT 112:216950
GI



I



II



III



I



II



III

AB The title compds. [I; Z = CR2CR3R4R5, C:CR6R7, CR8CR9:CR10R11; R1,R2,R8,R9 = H, alkyl; R3 = (un)substituted HO, halo, cyano, CO2H, alkoxycarbonyl, alkylamino, Q; m, n = 0, 1; A = (un)substituted alkylene or alkenylene; R4-R7,R10,R11 = H, alkoxycarbonyl, CO2H, Q, (un)substituted alkyl, alkenyl, or Ph; or R4R5, R6R7, R10R11 forming pyrrolidine or piperidine ring; or CR3R4R5 = COR5], useful for the treatment of active oxygen species (e.g. O2-.cntdot., H2O2, OH.cntdot., 1O2) - related inflammation and cardiovascular disease, e.g. arteriosclerosis, are prepd. Thus, treatment of 3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazine with (iso-Pr)2NLi in THF at -70.degree. followed by 3,5-di-tert-butyl-4-hydroxybenzaldehyde and warming the mixt. to room temp. and stirring 2 h at the room temp. gave threo- and erythro-benzothiazine deriv. (II). II and a (Z)-benzothiazine deriv. (III) inhibited the formation of lipid peroxides from ascorbic acid, ADP, Fe24, and rats' liver microsome in 0.04 M tris buffer with IC50 of 0.32 and 0.22 .mu.M, resp.

IT **126962-19-4**
RL: RCT (Reactant)
(hydrolysis of)

RN 126962-19-4 CAPLUS

CN Hexanenitrile, 6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





IT **126961-79-3P 126961-80-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 126961-79-3 CAPLUS
CN .alpha.-D-Galactopyranose, 6-deoxy-6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-1,2:3,4-bis-O-(1-methylethylidene)-, (6Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 126961-80-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-4-methyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **126961-97-5P 126961-98-6P 126961-99-7P**
126962-00-3P 126962-03-6P 126962-04-7P

126962-06-9P 126962-07-0P 126962-08-1P
126962-09-2P 126962-10-5P 126962-11-6P
126962-12-7P 126981-72-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for removal of active oxygen species and inhibition of lipid peroxide formation)

RN 126961-97-5 CAPLUS
CN .alpha.-D-Galactopyranose, 6-deoxy-6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-1,2:3,4-bis-O-(1-methylethylidene)-, (6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 126961-98-6 CAPLUS
CN Hexanoic acid, 6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 126961-99-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-hexylidene-4-methyl- (9CI) (CA INDEX NAME)



RN 126962-00-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(3,7-dimethyl-2,6-octadienylidene)-4-methyl- (9CI) (CA INDEX NAME)



RN 126962-03-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
4-methyl-2-[5-[(methylsulfonyl)oxy]pentylid
ene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 126962-04-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(5-iodopentylidene)-4-methyl-, (Z)-
(9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 126962-06-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[5-(diethylamino)pentylidene]-4-methyl-,
(Z)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 126962-05-8
CMF C18 H26 N2 O S
CDES 2:Z

Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 126962-07-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[5-(1,3-benzodioxol-5-yloxy)pentylidene]-
4-methyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 126962-08-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[5-[[2-(2,2-dimethyl-1,3-dioxolan-4-yl)-
2,5-dihydro-4-hydroxy-5-oxo-3-furanyl]oxy]pentylidene]-4-methyl- (9CI)
(CA INDEX NAME)



RN 126962-09-2 CAPLUS
CN .alpha.-D-Galactopyranoside, methyl
6-deoxy-6-(3,4-dihydro-4-methyl-3-oxo-

2H-1,4-benzothiazin-2-ylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 126962-10-5 CAPLUS
CN Hexanoic acid, 6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 126962-11-6 CAPLUS
CN Hexanenitrile, 6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)- (9CI) (CA INDEX NAME)



RN 126962-12-7 CAPLUS
CN Hexanoic acid, 6-(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 126981-72-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[3,5-bis(1,1-dimethylethyl)-4-

hydroxyphenyl]methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 21 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:534067 CAPLUS
DOCUMENT NUMBER: 111:134067
TITLE: A further synthetic pathway to 1,4-benzothiazin-3(4H)-ones; chlorinolysis of disulfides derived from .alpha.,.beta.-unsaturated carboxylic acid anilides
AUTHOR(S): Muehlstaedt, Manfred; Franke, Heike
CORPORATE SOURCE: Sekt. Chem., Karl-Marx-Univ., Leipzig, DDRk-7010, Ger. Dem. Rep.
SOURCE: Z. Chem. (1989), 29(4), 135-6
CODEN: ZECEAL; ISSN: 0044-2402
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 111:134067
GI



I



II

AB Treatment of 2-R1CH:CRCONHC6H4S2C6H4NHCOCR:CHR1-2 (R = Me, R1 = H; R = H, R1 = Ph, 4-MeOC6H4) with Cl gave the thaizinones I (R = Me, R1 = H; R = H, R1 = Ph) and II in 76-90% yield.

IT **122686-63-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by chlorination of acrylaminophenyl disulfide)

RN 122686-63-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[chloro(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 22 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:95053 CAPLUS
DOCUMENT NUMBER: 110:95053
TITLE: A novel synthetic route to phenyl-substituted pyridines. Synthesis of [1]benzopyrano[4,3-b]pyridines, [1]benzothiopyrano[4,3-b]pyridines and pyrido[3,2-b][1,4]benzothiazines(1-azapheothiazines) [Erratum to document cited in CA109(17):149389k]
AUTHOR(S): Tyndall, D. V.; Al Nakib, T.; Meegan, M. J.
CORPORATE SOURCE: Dep. Pharm. Chem., Trinity Coll. Dublin, Dublin, Ire.
SOURCE: Tetrahedron Lett. (1988), 29(42), 5330
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A text error has been cor. The error was not reflected in the abstr. or the index entries.
IT **24545-07-1**
RL: RCT (Reactant)
(cyclocondensation reaction of, with malononitrile (Erratum))
RN 24545-07-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 23 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:57296 CAPLUS
DOCUMENT NUMBER: 110:57296
TITLE: Preparation of hydroxystyrene derivatives as pharmaceuticals
INVENTOR(S): Shiraishi, Tadayoshi; Kameyama, Keiji; Domoto, Takeshi; Imai, Naohiro; Shimada, Yoshio; Ariki, Yutaka; Hosoe, Kazunori; Kawatsu, Masaji; Katsumi, Ikuo; et al.
PATENT ASSIGNEE(S): Kanegafuchi Chemical Industry Co., Ltd., Japan
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8807035	A1	19880922	WO 1988-JP254	19880310

W: JP, US
RW: BE, CH, DE, FR, GB, IT, NL, SE

EP 304493	A1	19890301	EP 1988-902540	19880310
EP 304493	B1	19920902		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 2539504	B2	19961002	JP 1988-502469	19880310
CA 1315783	A1	19930406	CA 1988-568136	19880530
US 4971996	A	19901120	US 1988-283992	19881110
US 5089516	A	19920218	US 1990-584683	19900919
US 5057538	A	19911015	US 1990-587147	19900924
US 5202341	A	19930413	US 1991-735581	19910725

PRIORITY APPLN. INFO.:
JP 1987-55965 19870311
JP 1987-55966 19870311
JP 1987-57256 19870312
WO 1988-JP254 19880310
US 1988-283992 19881110
US 1990-584683 19900919

OTHER SOURCE(S): MARPAT 110:57296

GI



I



II

AB The title compds. [I; R1 = OH, alkoxy, PhCH2O; R2 = PhCH2, etc.; or R1, R2 = Ph, PhCH2, PhCH2CH2, C1-3 alkyl; R3 = cyano; R4 = carbamoyl (R1, R2 .noteq. alkyl); R3R4 = 5- or 6-membered cyclic amide], useful as pharmaceuticals, are prepd. 3,5-Dibenzyl-4-hydroxybenzaldehyde and oxindole were dissolved in C6H6 and refluxed 5 h in the presence of piperidine and AcOH to give 29% (indolinylylidenemethyl)phenol II. II showed 78% inhibition (at 10 .mu.M) of guinea pig 5-lipoxygenase and 74% inhibition (at 1 .mu.M) of tyrosine kinase incubated with human cancer-cell stock A-431 as a proliferative acceptor. II had an acute toxicity LD50 of >500 mg/kg.

IT **118562-99-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as pharmaceutical)

RN 118562-99-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-hydroxy-3,5-bis(phenylmethyl)phenyl]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



Same as previous

L14 ANSWER 24 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:38945 CAPLUS

DOCUMENT NUMBER: 110:38945
TITLE: A new synthesis of pyrido[3,2-b][1,4]benzothiazines
AUTHOR(S): McCarthy, Eileen T.; Tyndall, D. Vivian; Meegan, Mary J.
CORPORATE SOURCE: Dep. Pharm. Chem., Trinity Coll. Dublin, Dublin, Ire.
SOURCE: J. Chem. Res., Synop. (1988), (5), 145
CODEN: JRPSDC; ISSN: 0308-2342
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:38945
GI



I



II

AB Cyclization of benzylidenebenzothiazinones I (e.g., R = C6H4Cl-p, C6H4OMe-p, 1-naphthyl, C6H4Ph-p) with NCCH2CN in MeOH contg. NaOH gave the title compds. II (R1 = Me). In EtOH contg. NaOH, I and NCCH2CN gave II (R1 = Et). A mechanism is proposed.

IT **24545-07-1P 54874-84-9P 54874-85-0P 95476-30-5P 95476-37-2P 101884-21-3P 118265-38-6P 118265-39-7P 118265-40-0P 118265-41-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of, with malononitrile, pyridobenzothiazine from)

RN 24545-07-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 54874-84-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-bromophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 54874-85-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 95476-30-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 95476-37-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 101884-21-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1-naphthalenylmethylene)- (9CI) (CA INDEX NAME)



RN 118265-38-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-fluorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 118265-39-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-([1,1'-biphenyl]-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 118265-40-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 118265-41-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-ethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:8144 CAPLUS
DOCUMENT NUMBER: 110:8144
TITLE: A novel, convenient synthesis of 2-aryl-3-oxo-3,4-dihydro-2H-1,4-benzothiazines
AUTHOR(S): Fujita, Masanobu; Ota, Atsutoshi; Ito, Susumu; Yamamoto, Koji; Kawashima, Yoichi
CORPORATE SOURCE: Res. Lab., Santen Pharm. Co., Ltd., Osaka, Japan
SOURCE: Synthesis (1988), (8), 599-604
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:8144
GI



I



II

AB Chlorodihydrobenzothiazinones I [R1 = H, Me, CHMe2; R2 = H, Me, (CH2)3NMe2, CH2CO2H] were treated with alkoxybenzenes, phenols, C6H6, and PhCl and AlCl3 to give arylated products II [R3 = anisyl, (MeO)2C6H3, Ph, ClC6H4, HOC6H4, HO(MeO)C6H3, HO(O2N)C6H3].

IT **117838-98-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 117838-98-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 26 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1988:549389 CAPLUS

DOCUMENT NUMBER: 109:149389

TITLE: A novel synthetic route to phenyl-substituted pyridines. Synthesis of [1]benzopyrano[4,3-b]pyridines, [1]benzothiopyrano[4,3-b]pyridines and pyrido[3,2-b][1,4]benzothiazines(1-azapheothiazines)

AUTHOR(S): Tyndall, D. V.; Nakib, T. Al; Meegan, M. J.

CORPORATE SOURCE: Dep. Pharm. Chem., Trinity Coll. Dublin, Dublin, Ire.

SOURCE: Tetrahedron Lett. (1988), 29(22), 2703-6
CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:149389

GI



II



III



IV



V

AB Reaction of PhCOCH:CHR (I; R = Ph, CH = CHPh, 1-naphthyl) with CH2(CN)2 in
the presence of piperidine gave pyrancarbonitriles II, whereas the reaction of I with CH2(CN)2 in the presence of NaOH in MeOH gave pyridinecarbonitriles III. This reaction was applied to a general synthesis of title compds. IV (X = O, S) and V from .alpha.,.beta.-unsatd.
ketones and CH2(CN)2.

IT **24545-07-1**
RL: RCT (Reactant)
(cyclocondensation reaction of, with malononitrile)

RN 24545-07-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 27 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1987:213918 CAPLUS

DOCUMENT NUMBER: 106:213918

TITLE: Diisopropylbenzylidene-substituted heterocycles

INVENTOR(S): Imai, Naohiro; Shiraishi, Tadayoshi; Katsumi, Ikuo; Yamashita, Katsuji; Ariki, Yutaka; Yamashita, Toshiaki

PATENT ASSIGNEE(S): Kanegafuchi Chemical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62029570	A2	19870207	JP 1985-167999	19850729
JP 05074587	B4	19931018		

GI



I



II

AB The title compds. I [R1 = H, PhCH2; R2 = H, R3CO (R3 = H, C1-3 alkyl), Ph;
X = CO, CS, C:NH, CHR4 (R4 = H, C1-3 alkyl), NPh; Y = CH2, CH2SO2, CO, C(O)NH, NR5 (R5 = H, C1-3 alkyl), NHC(O), O, S; XY = CR6:N (R6 = H, C1-3 alkyl, morpholino, Ph), N:CR6, o-phenylene, o-C6H4SO2], useful as antiallergics and tyrosine kinase inhibitors, are prepd. A mixt. of 3,5-(Me2CH)2C6H3CHO, hydantoin, ethanolamine, EtOH, and H2O was refluxed to give I (R1 = R2 = H, X = CO, Y = NH) which at 100 .mu.M showed 100% control of free slow-reacting substances of anaphylaxis or their biosynthesis in guinea pigs.

IT **108402-28-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiallergic agent and tyrosine kinase inhibitor)

RN 108402-28-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-hydroxy-3,5-bis(1-methylethyl)phenyl]methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



same as previous?

L14 ANSWER 28 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1987:138459 CAPLUS

DOCUMENT NUMBER: 106:138459

TITLE: Benzothiazinones

INVENTOR(S): Otsuka, Yozo; Naito, Kenji; Morita, Tadashi

PATENT ASSIGNEE(S): Tobishi Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61229874	A2	19861014	JP 1985-69106	19850403
JP 05033705	B4	19930520		

GI



I



II

AB Title compds. I [R = H, lower alkyl, 2-(dimethylamino)ethyl], useful as intermediates for the vasodilator diltiazem, were prepd. by treating cis-1-benzothiazepinones II with org. sulfonyl chlorides. Thus, treating 6.04 g 1-cis-II (R = H) with 5.7 g p-MeC6H4SO2Cl in pyridine gave 3.75 g I (R = H).

IT **87833-81-6P 95476-37-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for vasodilator diltiazem)

RN 87833-81-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



RN 95476-37-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 29 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1987:102191 CAPLUS

DOCUMENT NUMBER: 106:102191

TITLE: The synthesis of (3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetic acid and (3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid derivatives

AUTHOR(S): Teitei, Tsutomu

CORPORATE SOURCE: Div. Plant Ind., CSIRO, Canberra, 2601, Australia

SOURCE: Aust. J. Chem. (1986), 39(3), 503-10
CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:102191

GI



I



II



III

AB Reaction of o-aminophenol with various maleic anhydrides gave first 2-hydroxymaleanilic acids I (R, R1 = e.g. H, Cl), which were then converted into the benzoxazinones II (X = O; R1 = H; RR2 = bond) under mild basic conditions; similarly the reaction of o-aminothiophenol with the maleic anhydrides gave the benzothiazinones II in one step. The facile cycloaddn. and esterification of 2-hydroxymaleanlic acids to form the benzoxazines obsd. in this work is discussed in terms of the formation of the isomaleimide type intermediate III. None of the prepd. compds. showed significant activity on NADP-malic enzyme in the C4 photosynthetic pathway.

IT **106660-05-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and esterification of)
RN 106660-05-3 CAPLUS
CN Acetic acid, chloro(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **106660-06-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ethylation of)
RN 106660-06-4 CAPLUS
CN Acetic acid, chloro(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **37893-32-6P 106660-02-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 37893-32-6 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 106660-02-0 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **106660-01-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., isomerization and methylation of)
RN 106660-01-9 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, hydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



HCl

L14 ANSWER 30 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:571588 CAPLUS
DOCUMENT NUMBER: 105:171588
TITLE: Rearrangements and complex eliminations with 1,5-benzothiazepin-4-ones
AUTHOR(S): Kaupp, Gerd; Gruendken, E.; Matthies, D.
CORPORATE SOURCE: Fachbereich Chem. - Org. Chem. I, Univ. Oldenburg, Oldenburg, D-2900, Fed. Rep. Ger.
SOURCE: Chem. Ber. (1986), 119(10), 3109-20
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
GI


I


II


III


IV


V

AB New or rarely documented rearrangements and complex eliminations occur in the partially proton catalyzed pyrolysis of the benzothiazepinones I (R = H, Me, Ac) and II (R = H, Me, Ac). The reactions are classified and mechanistically discussed. The products and byproducts are spectrally characterized and their configurations are assigned based on their photolysis. III photodimerizes is soln. and in the cryst. state to give IV. V is remarkably insensitive to hydrolysis.

IT **55043-20-4P 55043-21-5P 104505-72-8P**
104505-73-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 55043-20-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-21-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 104505-72-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 104505-73-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 31 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1985:578283 CAPLUS
DOCUMENT NUMBER: 103:178283
TITLE: 1,5-Benzothiazepine derivatives
PATENT ASSIGNEE(S): Hamari Yakuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60072876	A2	19850424	JP 1983-181086	19830928

GI



I



II

AB Title compds. I [R = alkyl, (alkylamino)alkyl, morpholinoalkyl; R1-R3 = H, halo, OH, alkyl, alkoxy; X = halo] or their salts, useful as analgesics and antipyretics, were prepd. by treating II with Me3SiX (X = halo), H2O2, and H2O. Thus, 59.6 g 4,2-Cl(MeNH)C6H3SH, prepd. by N-methylation of 5-chloro-2-benzothiazolinone and subsequent hydrolysis, was treated with 34.0 g ClCH2CO2H to give 68.7 g 4-methyl-6-chloro-2H-1,4-benzothiazin-3(4H)-one, which (8.0 g) was refluxed with 5.1 g p-anisaldehyde and NaOMe gave 4.2 g II (R = Me; R1 = 4-OMe; R2 = R3 = H; X = Cl), which (1 g) was mixed with Me3SiCl and then treated with aq. H2O2 to give 650 mg I. The title compds. were 0.2-3 times as effective as pentazocine.

IT **95476-11-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ring expansion of, benzothiazepinediones from)

RN 95476-11-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-[(4-methoxyphenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



L14 ANSWER 32 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1985:542032 CAPLUS

DOCUMENT NUMBER: 103:142032

TITLE: 1,5-Benzothiazepine derivatives

PATENT ASSIGNEE(S): Hamari Yakuhin Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60072875	A2	19850424	JP 1983-181085	19830928

GI



I



II

AB Title compds. I [R = alkyl, (alkylamino)alkyl, morpholinoalkyl; R1-R3 = H,
halo, OH, alkyl, alkoxy] or their salts, useful as analgesic antipyretics,
were prepd. by treating II with Me3SiX (X = halo), H2O2, and H2O. Thus, treating 20 g 2H-1,4-benzothiazin-3(4H)-one with 33.4 g p-PhCH2OC6H4CHO and NaOMe gave 21.5 g II (R-R2 = H; R3 = OCH2Ph-4), which (4g) was treated
with 3.1 g N-(2-chloroethyl)morpholine to give 1.3 g II (R = 2-morpholinoethyl, R1 = R2 = H, R3 = 4-OH), which (1 g) was mixed with Me3SiCl and treated with aq. H2O2 to give the corresponding 0.4 g I.HCl. The analgesic activity of I was comparable to that of pentazocine.

IT **54874-55-4P 95476-30-5P 95476-31-6P 98448-63-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and alkylation of)

RN 54874-55-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2,4-dichlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 95476-30-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 95476-31-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 98448-63-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[4-(phenylmethoxy)phenyl]methylene]- (9CI) (CA INDEX NAME)



IT **98448-65-8P 98448-66-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ring expansion of, benzothiazepinediones from)
RN 98448-65-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-hydroxyphenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



RN 98448-66-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 33 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1985:132086 CAPLUS
DOCUMENT NUMBER: 102:132086
TITLE: 1,5-Benzothiazepine derivatives

INVENTOR(S): Maki, Yoshifumi; Sako, Magoichi; Mitsumori, Naomichi; Maeda, Sadayuki; Takaya, Masahiro
PATENT ASSIGNEE(S): Hamari Chemicals, Ltd., Japan
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4490292	A	19841225	US 1983-540000	19831007
EP 137083	A1	19850417	EP 1983-306147	19831011
EP 137083	B1	19870624		
R: CH, DE, FR, GB, LI				
CA 1225989	A1	19870825	CA 1983-438685	19831011

PRIORITY APPLN. INFO.: US 1983-540000 19831007
GI



I



II

AB 1,5-Benzothiazepine-3,4(5H)-diones I (R-R2 = H, halogen, alkyl, alkoxy, OH; R3 = CHCH:CH2, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylaminoalkyl, morpholinoalkyl, R4 = H, halogen) were prepd. by ring expansion of 2H-1,4-benzothiazin-3(4H)-ones II with trimethylhalosilane, H2O2, and water. Thus, 2H-1,4-benzothiazin-3(4H)-one was condensed with 2,4-Cl2C6H3CHO to give II (R = 2-Cl, R1 = 4-Cl, R2-R4 = H) which was alkylated with Me2NCH2CH2Cl to give II-HCl (R = 2-Cl, R1 = 4-Cl, R2 = R4 = H, R3 = Me2NCH2CH2). The latter compd. (1 g) in 10 mL CHCl3 at <0.degree. was treated with 2 mL Me3SiCl and 0.29 g 30% H2O2, stirred for 30 min, 1 mL water added, and the whole stirred 1 h at room temp. to give 1 g I (R = 2-Cl, R1 = 4-Cl, R2 = R4 = H, R3 = Me2NCH2CH2). I (R = R2 = R4 = H, R1 = 4-MeO, R3 = Me2NCH2CH2) at 60 mg/kg i.p. in mice gave 100% antagonism of the writhing syndrome induced by i.p. injection of 10 mL/kg 0.7% HOAc-saline soln. and, at 60 mg/kg i.p., decreased rectal temp. 1.1.degree. in rats with yeast-induced pyresis.

IT **95476-37-2**
RL: RCT (Reactant)
(alkylation of, with (chloroethyl)morpholine)

RN 95476-37-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



IT **54874-55-4P 54874-85-0P 95476-30-5P 95476-31-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and alkylation of, with (chloroethyl)morpholine)
RN 54874-55-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2,4-dichlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 54874-85-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 95476-30-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 95476-31-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



IT **95476-11-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ring enlargement of, benzothiazepine from)
RN 95476-11-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-[(4-methoxyphenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



IT **30752-17-1 85809-67-2**
RL: RCT (Reactant)
(ring enlargement of, benzothiazepine from)
RN 30752-17-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85809-67-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



L14 ANSWER 34 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1985:45965 CAPLUS
DOCUMENT NUMBER: 102:45965

TITLE: 1,4-Benzothiazines
PATENT ASSIGNEE(S): Hamari Yakuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59184170	A2	19841019	JP 1983-58457	19830401
JP 05059113	B4	19930830		

GI



I



II

AB The title compds. I (R = substituted alkyl; R1 = H, halo, alkoxy; R2 = H, Cl, OH, acyloxy; R3 = H, or R2R3 = O; R4 = OH, acyloxy), useful as analgesics and antipyretics (no data) were prepd. from the benzylidene derivs. II. Thus, heating a mixt. of 2 g II (R = Me, R1 = H), 3.3 g Pb(OAc)4, and benzene at 60.degree. for 3 h gave 2.0 g I (R = Me, R1 = R3 = H, R2 = R4 = AcO).

IT **30752-17-1**
RL: RCT (Reactant)
(acetoxylation of)

RN 30752-17-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 35 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1984:139162 CAPLUS
DOCUMENT NUMBER: 100:139162
TITLE: 1,5-Benzothiazepine derivatives
PATENT ASSIGNEE(S): Hamari Yakuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58206577	A2	19831201	JP 1982-89339	19820525

GI



I II III

AB 1,5-Benzothiazepine derivs. I [R, R1 = H, Me; Cl, Me; MeO, MeOCH2; MeO, Me2NCH2CH2 (free and HCl salt); MeO, HO; MeO, ClCH2CH2], useful as coronary vasodilators, antiarrhythmics, analgesics, and blood platelet aggregation inhibitors (no data), were prepd. by, e.g., treatment of II with H2O2, H2O, and Me3SiX (X = halo) followed by ring expansion of the resulting III. Thus, 1.43 mL Me3SiCl was added to a mixt. of 1 g II (R = H, R1 = Me) and 0.58 mL 30% aq. H2O2 in THF during 15 min at -20.degree. to -10.degree. and the whole stirred 4 h with ice cooling and then 2 h at room temp. to give 0.96 g III (R = H, R1 = Me, X = Cl), which (1 g) was treated with 1.04 g Ag2CO3 in Me2CO 30 min with ice cooling to give 0.73 g I (R = H, R1 = Me).

IT **30752-17-1**
RL: RCT (Reactant)
(chlorination-hydroxylation of)

RN 30752-17-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 36 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1984:85732 CAPLUS
DOCUMENT NUMBER: 100:85732

TITLE: 1,5-Benzothiazepines
PATENT ASSIGNEE(S): Hamari Yokuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58180476	A2	19831021	JP 1982-62918	19820414

GI



I



II

AB The title compds. I [R = H, halo, alkoxy; R1 = (substituted) alkyl, dialkylamino] were prepd. by, e.g., reaction of the benzothiazine derivs. II (R2R3 = p-RC6H4CH) with H2O2 and Me3SiX (X = halo) and ring enlargement of the resulting II (R2 = OH, R3 = p-RC6H4CHX). Thus, 1.43 mL Me3SiCl was added to a mixt. of 1 g II (R2R3 = PhCH, R1 = Me), 0.58 mL 30% H2O2, and 10 mL THF at -0 to -10.degree. over 15 min, the resulting mixt. stirred at room temp. for 2 h, and the resulting II (R2 = H, R3 = PhCHCl) (1 g) was treated with 1.04% Ag2CO3 with ice cooling for 30 min to give 0.73 g I (R = H, R1 = Me). I had coronary vasodilating, antiarrhythmic, analgesic and blood platelet aggregation-inhibiting activities (no data).

IT **30752-17-1**
RL: RCT (Reactant)
(reaction of, with trimethylsilyl chloride and hydrogen peroxide)

RN 30752-17-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 37 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1983:594934 CAPLUS
DOCUMENT NUMBER: 99:194934

TITLE: A simple ring expansion of 1,4-benzothiazines to give 1,5-benzothiazepines

AUTHOR(S): Maki, Yoshifumi; Sako, Magoichi; Mitsumori, Naomichi; Maeda, Sadayuki; Takaya, Masahiro

CORPORATE SOURCE: Gifu Coll. Pharm., Gifu, 502, Japan

SOURCE: J. Chem. Soc., Chem. Commun. (1983), (8), 450-1
CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



III

AB Addn. reaction of benzothiazinones I [RR1 = bond, R2 = H (II), OMe, Cl] with Me3SiOOH, generated in situ from Me3SiCl and H2O2, gave 90% I (R = OH, R1 = Cl, R2 as before), which underwent ring expansion on treatment with Ag2CO3 in THF at 0.degree. for 30 min to give benzothiazepines III (R2 as before) in high yields. III (R2 = H) was also prepd. from II by sequential oxidative addn. of AcOH, hydrolysis, and ring expansion by SOCl2. The ring expansion involves a episulfonium ion intermediate.

IT **87833-81-6**
RL: RCT (Reactant)
(chlorination/oxidn. of)

RN 87833-81-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



IT **30752-17-1**
RL: RCT (Reactant)
(oxidative acetylation and chlorination/oxidn. of)

RN 30752-17-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 38 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1983:215550 CAPLUS
DOCUMENT NUMBER: 98:215550
TITLE: Metalation of 2-alkylidene-3-oxo-1,4-benzothiazines at
the olefinic position and reactions with electrophiles
AUTHOR(S): Babudri, F.; Di Nunno, L.; Florio, S.
CORPORATE SOURCE: Ist. Chim. Org., Univ. Bari, Bari, I-70 126, Italy
SOURCE: Synthesis (1983), (3), 230-1
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Lithiation of I [R = Ph, 3,4-(MeO)2C6H3, R1 = H] by LiN(CHMe2)2 at -100.degree. gave intermediate I (R1 = Li) which reacted with electrophiles R2X (R2 = Et, PhCH2, H2C:CHCH2, X = Br; R2 = D, X = Cl; R2 = Me, X = iodo; R2X = Ac2O, PhSSPh) to give 50-92% of the corresponding I (R1 = R2). Allowing I (R = Ph, R1 = Li) to warm to room temp. gave 60% II.

IT **30752-17-1 85809-71-8**
RL: RCT (Reactant)
(metalation of, by lithium diisopropylamide)

RN 30752-17-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85809-71-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(3,4-dimethoxyphenyl)methylene]-4-methyl-

(9CI) (CA INDEX NAME)



IT **85810-72-6P 85810-73-7P 85810-74-8P**
85810-75-9P 85810-76-0P 85810-77-1P
85810-78-2P 85810-79-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 85810-72-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene-d)- (9CI) (CA INDEX NAME)



RN 85810-73-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(1-phenylethylidene)- (9CI) (CA
INDEX NAME)



RN 85810-74-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(1-phenylpropylidene)- (9CI) (CA INDEX NAME)



RN 85810-75-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1,2-diphenylethylidene)-4-methyl- (9CI) (CA INDEX NAME)



RN 85810-76-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(1-phenyl-3-butenylidene)- (9CI)
(CA INDEX NAME)



RN 85810-77-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(oxodiphenylethylidene)- (9CI) (CA INDEX NAME)



RN 85810-78-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[phenyl(phenylthio)methylene]- (9CI) (CA INDEX NAME)



RN 85810-79-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[1-(3,4-dimethoxyphenyl)ethylidene]-4-methyl- (9CI) (CA INDEX NAME)



L14 ANSWER 39 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1983:215549 CAPLUS
DOCUMENT NUMBER: 98:215549
TITLE: Stereoselective synthesis of 2-alkylidene-3,4-dihydro-3-oxo-2H-1,4-benzothiazines
AUTHOR(S): Babudri, F.; Di Nunno, L.; Florio, S.
CORPORATE SOURCE: Ist. Chim. Org., Univ. Bari, Bari, 70126, Italy
SOURCE: Tetrahedron (1982), 38(20), 3059-65
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



IV

AB Metalation of benzothiazine (I; R = H) (II) with LiN(CHMe2)2 followed by condensation reaction with aldehydes gave mixt. of diastereomeric aldols, which on acetylation and AcOH elimination gave high yields of the title compds., stereoselectively. E.g., metalation and reaction of II with PhCHO for 30 min gave 82% of a 1:1 mixt. of threo- and erythro-I [R = CH(OH)Ph], which on acetylation gave threo- and erythro-I [R = CH(OAc)Ph] (III), in 88 and 80% yield, resp. Elimination reaction of III gave 62% benzothiazine IV.

IT **30752-17-1P 85809-67-2P 85809-68-3P**

85809-69-4P 85809-70-7P 85809-71-8P
85809-72-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 30752-17-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85809-67-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]-4-methyl- (9CI) (CA INDEX NAME)



Same as previous

RN 85809-68-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(2-methylpropylidene)- (9CI) (CA INDEX NAME)



RN 85809-69-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-ethylbutylidene)-4-methyl- (9CI) (CA INDEX NAME)



RN 85809-70-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1,3-benzodioxol-5-ylmethylene)-4-methyl-

(9CI) (CA INDEX NAME)



RN 85809-71-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(3,4-dimethoxyphenyl)methylene]-4-methyl-
(9CI) (CA INDEX NAME)



RN 85809-72-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[(3-nitrophenyl)methylene]-
(9CI) (CA INDEX NAME)



L14 ANSWER 40 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1982:616104 CAPLUS
DOCUMENT NUMBER: 97:216104
TITLE: Structure of the bromination product of 2-ethyl-1,4-benzothiazin-3(4H)-one
AUTHOR(S): Bates, Robert B.; Duguay, Laurent M.; Klenck, Robert E.; Kriek, George R.; Tempesta, Michael S.; Brewer, Arthur D.
CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ, 85721, USA
SOURCE: J. Heterocycl. Chem. (1982), 19(4), 927-8
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Ethyl-1,4-benzothiazinone I and bromine react to give (Z)-(bromoethylidene)-1,4-benzothiazinone II which results from a complex bromination-oxidn. sequence. The structure II was detd. by an x-ray crystal structure anal.

IT **83715-98-4P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and crystal structure of)

RN 83715-98-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1-bromoethylidene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 41 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER:	1982:582315 CAPLUS
DOCUMENT NUMBER:	97:182315
TITLE:	Products from dimethyl hex-2-en-1-yne-1,6-dioate and dimethyl penta-2,3-diene-1,5-dioate with compounds possessing two adjacent nucleophilic centers
AUTHOR(S):	Acheson, R. Morrin; Wallis, John D.
CORPORATE SOURCE:	Dep. Biochem., Univ. Oxford, Oxford, OX1 3QU, UK
SOURCE:	J. Chem. Soc., Perkin Trans. 1 (1982), (8), 1905-14 CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE:	Journal
LANGUAGE:	English

GI



II



V

AB MeO2CC.tplbond.CCH:CHCO2Me (I) was sulfurized, mainly in the 5-position, by thioureas and thioamides. In some cases cis as well as trans addn. was obsd., even in MeOH. E.g., I with (MeNH)2CS in MeOH at room temp. for 6 h gave 52% II (R = E-CH:CHCO2Me, R1 = H) (III) and 1.6% II (R = H, R1 = E-CH:CHCO2Me) (IV): the same reaction in dry MeCN gave a 14:86 mixt. of III and IV. Imidazoline- and benzimidazole-2-thione reacted with I at the 4-position to give fused thiazinones. E.g., I with imidazoline-2-thione in warm MeCN gave 14.0% V. 2-Aminobenzothiazole, 2-aminothiazole, and 2-aminopyridine added to the 4-position of I via the ring N; subsequent cyclization gave fused pyrimidones. C6H4(NH2)2-1,2 (VI) and 2-H2NC6H4SH (VII) added at the 5-position, but addn. at the 4-position was followed by further Michael addn. to the 3-position. With (MeO2CCH:)2C, VI and VII gave cyclic compds. with an exocyclic unsatd. ester group, whereas thioureas gave derivs. of Me 4-oxothiazin-6-ylacetate.

IT **83443-74-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 83443-74-7 CAPLUS

CN 2-Butenoic acid, 4-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (Z,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 42 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1981:121569 CAPLUS

DOCUMENT NUMBER: 94:121569

TITLE: 2-Methylene-2,3-dihydro-3-oxo-4H-1,4-benzothiazine-1,1-dioxide compounds

INVENTOR(S): Eiden, Fritz; Meinel, Franz; Mayer, Dieter

PATENT ASSIGNEE(S): Thiemann, Dr., G.m.b.H. Chem.-Pharm. Fabrik, Fed. Rep. Ger.

SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2912445	A1	19801009	DE 1979-2912445	19790329

GI



I

AB Antiarrhythmic (no data) methylenebenzothiazinone dioxides I (R = H, alkyl; R1 = alkylthio; R2 = amino) were prepd. Thus, I (R = Me, R1 = R2 = SMe) was treated with morpholine to give 42% I (R = Me, R1 = SMe, R2 = morpholino).

IT **70685-34-6P 70685-35-7P 70685-36-8P**
76952-60-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 70685-34-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[(methylthio)-4-morpholinylmethylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 70685-35-7 CAPLUS

CN Propanedioic acid, [(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)(methylthio)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 70685-36-8 CAPLUS

CN Propanoic acid, 2-cyano-3-(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)-3-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 76952-60-8 CAPLUS
CN 2,4-Hexanedione, 6-(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)-6-(methylthio)- (9CI) (CA INDEX NAME)



IT **70685-33-5**
RL: RCT (Reactant)
(reaction of, with amines)
RN 70685-33-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[bis(methylthio)methylene]-4-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



L14 ANSWER 43 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:439408 CAPLUS
DOCUMENT NUMBER: 91:39408
TITLE: 2,3-Dihydro-1,4-benzothiazin-3-ones
AUTHOR(S): Eiden, Fritz; Meinel, Franz
CORPORATE SOURCE: Inst. Pharm. Lebensmittelchem., Univ. Muenchen, Munich, 8000/2, Fed. Rep. Ger.
SOURCE: Arch. Pharm. (Weinheim, Ger.) (1979), 312(4), 302-12
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I



II



III



IV

AB Title compds I (R = H, Me) and S-oxides and S,S-dioxides of I were prepd. e.g., by cyclocondensation of 2-HSC6H4NH2 with ClCH2CO2R1 (R1 = H, Et), followed by oxidn. and/or methylation. I (R = Me) reacted with carboxylic esters and NaH to give II (R2 = Me, Ph, COCO2Et; R3 = H). Reaction of II (R2 = Me, R3 = H) with H2O2-HOAc gave II (R3 = OAc). I or their oxides reacted with aldehydes; e.g., I (R = Me) and BzH gave III. I dioxide (R = Me) reacted with CS2-Me2SO4 to give IV (R4 = R5 = MeS) and with DMF di-Me acetal to give IV (R4 = Me2N, R5 = H).

IT **70685-26-6P 70685-27-7P 70685-28-8P 70685-29-9P 70685-33-5P 70685-34-6P 70685-35-7P 70685-36-8P 70685-37-9P 70685-38-0P 70685-39-1P 70685-40-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 70685-26-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(dimethylamino)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 70685-27-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(dimethylamino)methylene]-4-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 70685-28-8 CAPLUS

CN Benzaldehyde, 4-methoxy-, [(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]hydrazone (9CI) (CA INDEX NAME)



RN 70685-29-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(hydrazinomethylene)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 70685-33-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[bis(methylthio)methylene]-4-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 70685-34-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[(methylthio)-4-morpholinylmethylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 70685-35-7 CAPLUS
CN Propanedioic acid, [(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)(methylthio)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 70685-36-8 CAPLUS
CN Propanoic acid, 2-cyano-3-(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)-3-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 70685-37-9 CAPLUS
CN Propanenitrile, 3-(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)-3-(methylthio)- (9CI) (CA INDEX NAME)



RN 70685-38-0 CAPLUS
CN 2,4-Pentanedione, 3-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-2-ylidene)(methylthio)methyl]- (9CI) (CA INDEX NAME)



RN 70685-39-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-
2H-1,4-benzothiazin-2-ylidene)(methylthio)methyl]-4-methyl-, 1,1-dioxide
(9CI) (CA INDEX NAME)



RN 70685-40-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[amino(3,4-dihydro-4-methyl-1,1-dioxido-3-
oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-4-methyl-, 1,1-dioxide (9CI)
(CA INDEX NAME)



L14 ANSWER 44 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:152210 CAPLUS
DOCUMENT NUMBER: 90:152210
TITLE: 2-Phenacylidenebenzo-1,4-thiazin-3-ones
INVENTOR(S): Andreichikov, Yu. S.; Tendryakova, S. P.; Nalimova, Yu. A.; Voronova, L. A.; Vilenchik, Ya. M.
PATENT ASSIGNEE(S): Perm Pharmaceutical Institute, USSR
SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1978, 55(40), 78.
CODEN: URXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 630254	T	19781030	SU 1976-2361368	19760518

GI



I

AB The prepn. of title compds. I (R = Ph, p-tolyl, p-MeOC6H4, BrC6H4) by treating o-HSC6H4NH2 with a dicarbonyl deriv. in an org. solvent was improved by using the corresponding 5-aryl-2,3-furandione as the dicarbonyl deriv. in C6H6.

IT **64393-75-5P 64393-76-6P 64393-77-7P 64393-80-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 64393-75-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-oxo-2-phenylethylidene)- (9CI) (CA INDEX NAME)



RN 64393-76-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-methylphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-77-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-methoxyphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-80-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-bromophenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



L14 ANSWER 45 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1979:54901 CAPLUS
DOCUMENT NUMBER: 90:54901
TITLE: Studies of the blue color of some mesoionic 1,3-thiazolo[3,2-a]-4-quinazolones
AUTHOR(S): Talukdar, P. B.; Sengupta, S. K.; Datta, A. K.
CORPORATE SOURCE: Res. Dev. Div., East India Pharm. Works Ltd., Calcutta, India
SOURCE: Indian J. Chem., Sect. B (1978), 16B(8), 678-82
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Synthetic studies on the blue color of mesoionic thiazolo[3,2-a]-4-quinazolones (I, R = e.g. p-MeC6H4) suggest that an aryl type substituent at N-3 and a polar CO group at N-1 in the 4-quinazolone residue are essential structural features necessary for the development of a blue color. Whereas 9-mercaptophenanthridine gives a stable orange-yellow compd., attempted synthesis of similar fused ring mesoionic systems from 1,8-naphthyridine, 1,4-benzothiazine and quinoxaline derivs. yield highly sensitive unstable compds.
IT **69001-93-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with sodium chloroacetate)
RN 69001-93-0 CAPLUS
CN 2H-1,4-Benzothiazine-3(4H)-thione, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 46 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1978:529528 CAPLUS
DOCUMENT NUMBER: 89:129528
TITLE: 2-Phenacylidenebenzo-1,4-thiazin-3-ones
INVENTOR(S): Andreichikov, Yu. S.; Tendryakova, S. P.; Nalimova, Yu. A.; Voronova, L. A.
PATENT ASSIGNEE(S): Perm Pharmaceutical Institute, USSR
SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1978, 55(26), 76.
CODEN: URXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 615071	T	19780715	SU 1975-2154320	19750708

GI



I

AB Title compds. I (R = H, Me, MeO, Et, Br) were prepd. by treating o-H2NC4H4SH with p-RC6H4COCH2COCO2H at 95-105.degree. in dioxane.

IT **64393-75-5P 64393-76-6P 64393-77-7P 64393-78-8P 64393-80-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 64393-75-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-oxo-2-phenylethylidene)- (9CI) (CA INDEX NAME)



RN 64393-76-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-methylphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-77-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-methoxyphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-78-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-ethylphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-80-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-bromophenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



L14 ANSWER 47 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1978:509526 CAPLUS
DOCUMENT NUMBER: 89:109526
TITLE: Substituted 2H-1,4-benzothiazin-3(4H)-ones
INVENTOR(S): Krapcho, John
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4078062	A	19780307	US 1976-736620	19761028

GI



I

AB The title compds. I (R = H, alkyl, aralkyl, R1 = H, halo, alkyl, alkoxy, CF3, NH2, NO2, R2 = dialkylamino, piperidino, morpholino, alkylpiperazinyl, n = 2-5), useful as inflammation inhibitors, were prepd.
by condensing 4-methyl-1,4-benzothiazin-3(4H)-one with R2(CH2)nOC6H4CHO, isolated as the hydrochlorides.

IT **66820-19-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and inflammation inhibiting activity of)

RN 66820-19-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[3-(dimethylamino)propoxy]phenyl]methylene]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **66820-21-1P 66820-24-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and inflammation-inhibiting activity of)
RN 66820-21-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[2-(dimethylamino)ethoxy]phenyl]methy
lene]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 66820-24-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[2-(dimethylamino)ethoxy]phenyl]methy
lene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **66820-18-6P 66820-20-0P 66820-22-2P**
66820-23-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and salt formation from)
RN 66820-18-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[3-(dimethylamino)propoxy]phenyl]meth
ylene]-4-methyl-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 66820-17-5
CMF C21 H24 N2 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 66820-20-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[2-(dimethylamino)ethoxy]phenyl]methy
lene]-4-methyl- (9CI) (CA INDEX NAME)



RN 66820-22-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[3-(dimethylamino)propoxy]phenyl]meth
ylene]- (9CI) (CA INDEX NAME)



RN 66820-23-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[4-[2-(dimethylamino)ethoxy]phenyl]methy
lene]- (9CI) (CA INDEX NAME)



L14 ANSWER 48 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1978:405576 CAPLUS
DOCUMENT NUMBER: 89:5576
TITLE: Carbon-13 NMR spectroscopy, part 19. Structures of addition products of acetylenedicarboxylic acid esters with various dinucleophiles. An application of C,H-spin-coupling constants
AUTHOR(S): Voegeli, Ulrich; Von Philipsborn, Wolfgang; Nagarajan, Kuppuswamy; Nair, Mohan D.
CORPORATE SOURCE: Inst. Org. Chem., Univ. Zurich, Zurich, Switz.
SOURCE: Helv. Chim. Acta (1978), 61(2), 607-17
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Heterocyclic compds. of the general types I, II, and III (R = alkyl), obtained by addn. reaction of acetylenedicarboxylate esters with thioureas, cyclic amidines, etc., were studied by C-13 NMR. Constitutional isomers were distinguished by C-H spin coupling consts. Configurations of trisubstituted exocyclic C-C double bonds were detd.

IT **37893-72-4 66628-74-8**
RL: PRP (Properties)
(NMR of)

RN 37893-72-4 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 66628-74-8 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 49 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1978:50888 CAPLUS
DOCUMENT NUMBER: 88:50888
TITLE: Acylaminopenicillins
INVENTOR(S): Kuramoto, Masashi; Yaso, Masao; Sakeko, Magoichi; Saito, Satoshi; Yamaguchi, Tsutomu; Maki, Hirofumi
PATENT ASSIGNEE(S): Toyo Jozo Co., Ltd., Japan
SOURCE: Japan. Kokai, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52091888	A2	19770802	JP 1976-8740	19760128

GI



I



II

AB Two title compds. I (R = H, OH) were prepd. by reaction of ampicillin or amoxicillin with II or its derivs. Thus, 0.18 mL ClCO2Et and a mixt. of 0.44 g II and Et3N in DMF (ice-NaCl cooled) were stirred 20 min, a mixt. of 0.8 g ampicillin-3H2O and Et3N in DMF added, and the whole stirred 5 h at room temp. to give 1.05 g I (R = H) (III). Min. growth inhibitory concn. of III against Pseudomonas pyocyanea was 6.2 mcg/mL.

IT **63351-92-8**
RL: RCT (Reactant)
(acylation of ampicillin by)

RN 63351-92-8 CAPLUS

CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)- (9CI) (CA INDEX NAME)



IT **65283-01-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)

RN 65283-01-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)acetyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **65283-02-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 65283-02-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)acetyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L14 ANSWER 50 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1977:567957 CAPLUS
DOCUMENT NUMBER: 87:167957
TITLE: Chemistry of oxalyl derivatives of methyl ketones. V.
Reaction of aroylpyruvic acids and their derivatives with o-aminothiophenol
AUTHOR(S): Andreichikov, O. S.; Tendryakova, S. P.; Nalimova, Yu.
A.; Voronova, L. A.
CORPORATE SOURCE: Perm. Farm. Inst., Perm, USSR
SOURCE: Khim. Geterotsikl. Soedin. (1977), (6), 755-7
CODEN: KGSSAQ
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I



II

AB Benzothiazinones I (R = H, Me, MeO, Et, Cl, Br, F) were obtained in 72-82% yields by cyclocondensation p-RC6H4COCH2COCO2H with o-H2NC6H4SH. I (R = H, Me, MeO, Br) were obtained in 76-98% yields by cyclocondensation of the corresponding 5-aryl-2,3-furandione with o-H2NC6H4SH. Benzothiazolines II (R1 = H, Me, MeO, Cl) were obtained in 85-98% yields by cyclocondensation of p-R1C6H4COCH2COCO2Me with o-H2NC6H4SH.

IT **64393-75-5P 64393-76-6P 64393-77-7P**
64393-78-8P 64393-79-9P 64393-80-2P
64393-81-3P
RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 64393-75-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-oxo-2-phenylethylidene)- (9CI) (CA INDEX NAME)



RN 64393-76-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-methylphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-77-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-methoxyphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-78-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-ethylphenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-79-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-chlorophenyl)-2-oxoethylidene]- (9CI) (CA INDEX NAME)



RN 64393-80-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-bromophenyl)-2-oxoethylidene]-
(9CI) (CA INDEX NAME)



RN 64393-81-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(4-fluorophenyl)-2-oxoethylidene]-
(9CI) (CA INDEX NAME)



L14 ANSWER 51 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1977:468378 CAPLUS
DOCUMENT NUMBER: 87:68378
TITLE: .alpha.-Acylamidobenzylpenicillins
INVENTOR(S): Kuramoto, Masashi; Yaso, Masao; Sakou, Magoichi; Saito, Tetsu; Yamaguchi, Tsutomu; Maki, Yoshifumi
PATENT ASSIGNEE(S): Toyo Jozo Co., Ltd., Japan
SOURCE: Japan. Kokai, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51133298	A2	19761118	JP 1975-58239	19750515

GI



I



II

AB I (R = H, OH) Na salts were prepd. by acylating .alpha.-aminobenzylpenicillins or their salts with II or its reactive derivs. I (R = H) inhibited the growth of Pseudomonas pyocyanea NCTC 10490 at 0.2 .mu.g/mL. Thus, 0.44 g II was activated with ClCO2Et-Et3N in DMF and stirred with 0.8 g ampicillin-3H2O to give 1.05 g I (R = H) Na salt.

IT **63351-92-8**
RL: RCT (Reactant)
(acylation of ampicillin amd amoxycillin by)

RN 63351-92-8 CAPLUS

CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)- (9CI) (CA INDEX NAME)



IT **63351-93-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)

RN 63351-93-9 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)acetyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● Na

IT **63397-82-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 63397-82-0 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
6-[[[[(3,4-dihydro-3-
oxo-2H-1,4-benzothiazin-2-ylidene)acetyl]amino](4-
hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt,
[2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● Na

L14 ANSWER 52 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1977:105433 CAPLUS
DOCUMENT NUMBER: 86:105433
TITLE: Facile thermal dimerization of a photochemically isomerized olefin
AUTHOR(S): Maki, Yoshifumi; Sako, Magoichi
CORPORATE SOURCE: Gifu Coll. Pharm., Gifu, Japan
SOURCE: Chem. Pharm. Bull. (1976), 24(9), 2250-3
CODEN: CPBTAL
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB In sharp contrast to the Z form of I, the photochem.-produced isomer, E-I,
underwent a facile thermal dimerization to form a cyclobutane deriv. Thus, the apparent photodimerization of Z-I involves primarily the thermal
dimerization of its photochem. produced isomer.

IT **37893-72-4**
RL: RCT (Reactant)
(methylation of)

RN 37893-72-4 CAPLUS

CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **61955-27-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and photochem. cyclodimerization of)

RN 61955-27-9 CAPLUS

CN Acetic acid, (3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **61955-26-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and photoisomerization of)

RN 61955-26-8 CAPLUS

CN Acetic acid, (3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **61960-48-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 61960-48-3 CAPLUS
CN Acetic acid, (3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (E)-, dimer (9CI) (CA INDEX NAME)

CM 1

CRN 61955-27-9
CMF C12 H11 N O3 S
CDES 2:E

Double bond geometry as shown.



L14 ANSWER 53 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1976:74279 CAPLUS
DOCUMENT NUMBER: 84:74279
TITLE: 3,4-Dihydro-3-oxo-2H-1,4-benzothiazines and benzoxazines
INVENTOR(S): Worley, Jimmy W.
PATENT ASSIGNEE(S): Monsanto Co., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3923709	A	19751202	US 1974-502114	19740830

GI For diagram(s), see printed CA Issue.
AB The benzothiazines I (R = CH2CO2Et, X = m-F3CC6H4CH, 3,4-methylenedioxybenzylidene, p-MeOC6H4CH, m-O2NC6H4CH, 2,4-Cl2C6H3CH) were prepd. by reaction of I [R = CH2CO2Et, X = H,P(O)(OEt)2] with aldehydes. I [R = CH2CO2Et; 3,5-(MeO)2C6H3CH, 3,4,5-(MeO)3C6H2CH, PhCH, cyclohexylidene, Me2C, etc.] were prepd. by treating I [R = H, X = H,P(O)(OEt)2] with aldehydes followed by bromoacetates. Et 3,4-dihydro-2-(p-chlorobenzylidene)-3-oxo-2H-1,4-benzoxazine-4-acetate was
similarly prepd. In preemergence application at 4-10 lbs/acre I

controlled broadleaf plants.

IT **58216-00-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction with bromoacetate)

RN 58216-00-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 74 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1976:59503 CAPLUS

DOCUMENT NUMBER: 84:59503

TITLE: 2-Substituted methylene-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-4-acetic acid and esters

INVENTOR(S): Worley, Jimmy W.

PATENT ASSIGNEE(S): monsanto, USA

SOURCE: U.S., 3 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3910904	A	19751007	US 1974-496507	19740812

GI For diagram(s), see printed CA Issue.

AB Four benzothiazines I (X = H, CO2R; R = H, Me, Et; R1 = H, Et), useful in regulation of plant growth, e.g., soybeans, were prepd., where X = H, by reaction of 2-[(alkoxycarbonyl)methylene]-3,4-dihydro-3-oxo-2H-1,4-benzothiazine with BrCH2CO2Et in Me2CO at reflux in the presence of KOH (optionally followed by hydrolysis), and where X = CO2R, by reaction of 2-chloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazine with P(OEt)3 at 100.degree. and sequentially treating the product with CO(CO2Et)2 in EtOH contg. EtONa and with BrCH2CO2Et in Me2CO-KOH.

IT **55043-52-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, with ethyl bromoacetate)

RN 55043-52-2 CAPLUS

CN Propanedioic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, diethyl ester (9CI) (CA INDEX NAME)



IT **13677-06-0 54255-33-3**
RL: RCT (Reactant)
(reaction of, with ethyl bromoacetate)
RN 13677-06-0 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 54255-33-3 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 55 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1975:443441 CAPLUS
DOCUMENT NUMBER: 83:43441
TITLE: 2-Dialkylphosphonyl- and 2-alkylidene-3,4-dihydro-3-oxo-2H-1,4-benzothiazines
AUTHOR(S): Worley, J. W.; Ratts, K. Wayne; Cammack, K. L.
CORPORATE SOURCE: Res. Dep., Monsanto Agric. Prod. Co., St. Louis, Mo., USA
SOURCE: J. Org. Chem. (1975), 40(12), 1731-4
CODEN: JOCEAH
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Benzothiazinylphosphonates [I, R = H, Me, CH2CO2Et; R1 = P(O)(OEt)2] were prepd. by the Michaelis-Arbuzov reaction of P(OEt)3 with I(R1 = Cl). I [R1 = P(O)(OEt)2] reacts with R2CHO (R2 = H, Ph, substituted phenyl, 2-thienyl, 9-anthryl, PhCH:CH) to give (Z)-II.
IT **55043-20-4P 55043-21-5P 55043-22-6P**
55043-23-7P 55043-24-8P 55043-25-9P
55043-26-0P 55043-28-2P 55043-29-3P
55043-30-6P 55043-31-7P 55043-51-1P
55043-52-2P 55043-53-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 55043-20-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-21-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-22-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[(4-methylphenyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-23-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-(1,3-benzodioxol-5-ylmethylene)-4-methyl-
, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-24-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(2-thienylmethylene)-, (Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-25-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1,3-benzodioxol-5-ylmethylene)-, (Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



Provisional

RN 55043-26-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-methoxyphenyl)methylene]-, (2Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-28-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-fluorophenyl)methylene]-4-methyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-29-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[(2-nitrophenyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-30-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(9-anthracenylmethylene)-4-methyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 55043-31-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(3-phenyl-2-propenylidene)-, (Z,?)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 55043-51-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-methylene- (9CI) (CA INDEX NAME)



RN 55043-52-2 CAPLUS
CN Propanedioic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, diethyl ester (9CI) (CA INDEX NAME)



RN 55043-53-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1-methylethylidene)- (9CI) (CA INDEX NAME)



L14 ANSWER 56 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1975:141592 CAPLUS
DOCUMENT NUMBER: 82:141592
TITLE: Heterocyclic coloring matters. II. .DELTA.2,2-Bi(2H-1,4-benzothiazines)
AUTHOR(S): Kaul, B. L.
CORPORATE SOURCE: Dyes Dep.-Dyes Chem. Res., Sandoz Ltd., Basel, Switz.
SOURCE: Helv. Chim. Acta (1974), 57(8), 2664-78
CODEN: HCACAV
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Dyes (I, R = H, Br, Cl, Me, MeO, CF3; R1=H, Me, MeO, EtO) having the .DELTA.2,2'-bi(3,4-dihydro-3-oxo-2H-1,4-benzothiazine) chromophore were prepd. by the one-step reaction of 2,3-dichloromaleic acid [1122-17-4] with zinc salts of o-aminobenzenethiol derivs. The structure, substitution reactions, mechanism of formation, color, and other relevant properties of the system were detd. and compared to known thioindigos. A synthesis of the basic skeleton of one of the Trichosiderins, the coloring matter of human red hair was described.
IT **54392-69-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 54392-69-7 CAPLUS
CN Acetic acid, chloro(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-(9CI) (CA INDEX NAME)



L14 ANSWER 57 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1975:140162 CAPLUS
DOCUMENT NUMBER: 82:140162
TITLE: 2-Arylmethylene-1,4-benzothiazin-3(4H)-ones
INVENTOR(S): Anzai, Naomichi; Ishii, Tadao; Shibata, Uichi; Seki, Shigeo
SOURCE: Japan. Kokai, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49101389	A2	19740925	JP 1973-15660	19730209

JP 57053350 B4 19821112

GI For diagram(s), see printed CA Issue.

AB Title compds. I (R = Ph, MeOC6H4, O2NC6H4, BrC6H4, ClC6H4, Cl2C6H3, thienyl, furyl) are prepd. by condensation of 2H-1,4-benzothiazin-3(4H)-one (II) and arom. aldehydes. I had antiinflammatory effect in rats and were effective against HeLa cells and Trichomonas vaginalis. Thus, 1.7 g II was dissolved in 100 ml 2% KOH-EtOH and heated with 1.1 g BzH at 70.degree. for 2 hr to give 82.6% I (R = Ph). Among 8 more I prepd. were those where R = o-MeOC6H4, p-O2NC6H4, 2,4-Cl2C6H3, and 2-thienyl.

IT **24545-07-1P 50393-32-3P 54874-53-2P**
54874-54-3P 54874-55-4P 54874-62-3P
54874-84-9P 54874-85-0P 54913-29-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 24545-07-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 50393-32-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 54874-53-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 54874-54-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)





RN 54874-55-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2,4-dichlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 54874-62-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-furanylmethylene)- (9CI) (CA INDEX NAME)



RN 54874-84-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-bromophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 54874-85-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(4-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 54913-29-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



L14 ANSWER 58 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1974:552071 CAPLUS
DOCUMENT NUMBER: 81:152071
TITLE: Fungicides. XXIV. Reaction of 5-methoxycarbonylmethylidene-2-thioxo(or oxo)-4-thiazolidones with o-aminobenzenethiol and other thiols
AUTHOR(S): Nagase, Hiroshi
CORPORATE SOURCE: Agric. Chem. Div., Takeda Chem. Ind., Ltd., Osaka, Japan
SOURCE: Chem. Pharm. Bull. (1974), 22(1), 42-9
CODEN: CPBTAL
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB A novel addn. reaction of .omicron.-aminobenzenethiol to 5-methoxycarbonylmethylene-2-thioxo-(or oxo)-4-thiazolidones (I) gave 3-methyl (or benzyl)-5-(3-oxo-2,3-dihydro-4H-1,4-benzothiazin-2-yl)-2-thioxo(or oxo)-4-thiazolidones (II). I also reacted with thiols to afford 1:1 adducts (III and IV) in the presence of a catalytic amt. of NEt3. Thermal cyclization of the adducts III to II was observed. The adducts IV dissocd. into I and thiols when heated above their m.p. or dissolved in acetone or ethanol. Oxidn. of II and IV gave the dehydro-compds. V and VI, resp.
IT **54255-33-3**
RL: RCT (Reactant)
(reaction with triethylammonium benzyldithiocarbamate)
RN 54255-33-3 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 59 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:542782 CAPLUS
DOCUMENT NUMBER: 79:142782
TITLE: 4-[3-(Dimethylamino)propyl]-3,4-dihydro-2-(1-hydroxyethyl)-3-phenyl-2H-1,4-benzothiazine and related compounds. New class of antiinflammatory agents
AUTHOR(S): Krapcho, John; Turk, Chester F.

CORPORATE SOURCE: Squibb Inst. Med. Res., Princeton, N. J., USA
SOURCE: J. Med. Chem. (1973), 16(7), 776-9
CODEN: JMCMAR
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several of 23 benzothiazines synthesized show significant antiinflammatory activity in rats, the most potent being 4-[3-(dimethylamino)propyl]-3,4-dihydro-2-(1-hydroxyethyl)-3-phenyl-2H-1,4-benzothiazine-HCl (I-HCl) [42585-60-4] and 2-acetyl-4-[3-(dimethylamino)propyl]-3,4-dihydro-3-phenyl-2H-1,4-benzothiazine-HCl (II-HCl) [42381-03-3]. I and II inhibited carrageenin-induced rat paw edema at 55 and 65 mg/kg orally, respectively.

To synthesize I, 2-aminobenzenethiol [137-07-5] was condensed with chloroacetic acid [79-11-8] to form 1,4-benzothiazin-3(4H)-one [5325-20-2], then with BzH to form the 2-benzylidene deriv. and with 3-dimethylaminopropyl chloride [109-54-6] to attach the side chain. Interaction with MeMgBr followed by aq. NH4Cl and heating resulted in rearrangement to II, redn. of which with NaBH4 yielded I.

IT **33216-62-5P 50346-41-3P 50346-42-4P 50346-43-5P 50393-32-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 33216-62-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-pyridinylmethylene)- (9CI) (CA INDEX NAME)



RN 50346-41-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(3-pyridinylmethylene)- (9CI) (CA INDEX NAME)



RN 50346-42-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(4-pyridinylmethylene)- (9CI) (CA INDEX NAME)



RN 50346-43-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-(phenylmethylene)- (9CI) (CA

INDEX NAME)



RN 50393-32-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



IT **24545-07-1**
RL: RCT (Reactant)
(reaction of, with dimethylaminopropyl chloride)
RN 24545-07-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 60 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:124527 CAPLUS
DOCUMENT NUMBER: 78:124527
TITLE: Reaction of the Vilsmeier product, 3-chloro-2-dimethylaminomethylene-1,4-benzothiazene, with aromatic amines and active methylene compounds
AUTHOR(S): Shah, S. R.; Seshadri, S.
CORPORATE SOURCE: Dep. Chem. Technol., Univ. Bombay, India
SOURCE: Indian J. Chem. (1972), 10(10), 977-81
CODEN: IJOCAP
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The reaction of 3-chloro-2-dimethylaminomethylene-1,4-benzothiazine (I) with aromatic amines in HOAc was studied. The reaction with aniline and with p-chloroaniline in the presence of pyridine gave 2-anilinomethylene-1,4-benzothiazin-3(4H)-ones (II, R = H, Cl, resp.) and the 2-formyl-3-anilino-1,4-benzothiazines (III, R = H, Cl, resp.). The reaction with weakly basic aromatic amines proceeded directly (with- out involving rearrangement) to give anilinomethylenebenzothiazinones. The reaction of I with some active methylene compds. in HOAc in the presence of pyridine was studied.
IT **41526-80-1P 41526-81-2P 41526-85-6P**
41526-86-7P 41526-87-8P 41526-88-9P
41526-89-0P 41526-90-3P 41526-91-4P
41526-92-5P 41526-93-6P 41526-94-7P

41526-95-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 41526-80-1 CAPLUS
CN Pyridinium, 1-[[3-(phenylamino)-2H-1,4-benzothiazin-2-ylidene]methyl]-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 50577-48-5
CMF C20 H16 N3 S



CM 2

CRN 14797-73-0
CMF Cl O4



RN 41526-81-2 CAPLUS
CN Pyridinium, 1-[[3-[(4-chlorophenyl)amino]-2H-1,4-benzothiazin-2-ylidene]methyl]-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 48209-78-5
CMF C20 H15 Cl N3 S



CM 2

CRN 14797-73-0
CMF Cl O4



RN 41526-85-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(phenylamino)methylene]- (9CI) (CA INDEX NAME)



RN 41526-86-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-chlorophenyl)amino]methylene]- (9CI)
(CA INDEX NAME)



RN 41526-87-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-methoxyphenyl)amino]methylene]- (9CI) (CA INDEX NAME)



RN 41526-88-9 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(2-nitrophenyl)amino]methylene]- (9CI) (CA INDEX NAME)



RN 41526-89-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(3-nitrophenyl)amino]methylene]- (9CI)

(CA INDEX NAME)



RN 41526-90-3 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-nitrophenyl)amino]methylene]- (9CI) (CA INDEX NAME)



RN 41526-91-4 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(2-methoxy-4-nitrophenyl)amino]methylene]- (9CI) (CA INDEX NAME)



RN 41526-92-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-methoxy-2-nitrophenyl)amino]methylene]- (9CI) (CA INDEX NAME)



RN 41526-93-6 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(4-chloro-2-nitrophenyl)amino]methylene]- (9CI) (CA INDEX NAME)





RN 41526-94-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[(2,5-dichlorophenyl)amino]methylene]-(9CI) (CA INDEX NAME)



RN 41526-95-8 CAPLUS
CN Benzoic acid, 2-[[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]amino]- (9CI) (CA INDEX NAME)



L14 ANSWER 61 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:84341 CAPLUS
DOCUMENT NUMBER: 78:84341
TITLE: Reactions of Vilsmeier product, 3-chloro-2-dimethylaminomethylene-1,4-benzothiazine derived from 1,4-benzothiazin-3(4H)-one
AUTHOR(S): Shah, S. R.; Seshadri, S.
CORPORATE SOURCE: Dep. Chem. Technol., Univ. Bombay, Matunga, India
SOURCE: Indian J. Chem. (1972), 10(8), 820-2
CODEN: IJOCAP
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The properties of 3-chloro-2-(dimethylaminomethylene)-1,4-benzothiazine (I, R = Cl) (II) [the Vilsmeier product derived from 1,4-benzothiazin-3(4H)-one] are described. Hydrolysis under different conditions gave 1,4-benzothiazine-2-carboxylic acid (III, R = H, R1 = CO2H), 1,4-benzothiazin-3(4H)-one-2-carboxaldehyde, or 3-chloro-1,4-benzothiazine-2-carboxaldehyde III (R = H, R1 = CHO), depending on the method of hydrolysis. Reaction of the perchlorate of II with pyridine leads to the selective attack at the aminomethylene function yielding a pyridinium salt (IV), but reaction with Me2SO leads to the displacement of chlorine yielding a dimethylsulphoxonium deriv. I (R = Me2S+O)ClO4-. Reaction of

II with NaOAc or KCN in HOAc gave the benzothiazinones (V, R = OAc, CN, resp.).

IT **39974-42-0P 39974-43-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 39974-42-0 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(acetyloxy)methylene]- (9CI) (CA INDEX NAME)



RN 39974-43-1 CAPLUS
CN Acetonitrile, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)- (9CI) (CA INDEX NAME)



L14 ANSWER 62 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1972:461922 CAPLUS
DOCUMENT NUMBER: 77:61922
TITLE: Reaction of 2-aminothiophenol with dimethyl acetylenedicarboxylate
AUTHOR(S): Maki, Yoshifumi; Suzuki, Mikio
CORPORATE SOURCE: Gifu Coll. Pharm., Gifu, Japan
SOURCE: Chem. Pharm. Bull. (1972), 20(4), 832-4
CODEN: CPBTAL
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Osc-H2NC6H4SH (I) and MeO2CC.tplbond.CCO2Me (II) gave benzothiazine (trans-III) (IV), which was photochem. isomerized to cis-III (V). Hydrogenation of IV gave VI. Photochem. addn. of I and II gave IV, V, and di-Me fumarate, as well as other products.

IT **37893-72-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 37893-72-4 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 63 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1972:461917 CAPLUS
DOCUMENT NUMBER: 77:61917
TITLE: Aminobenzenes. VIII. Rearrangement of phenyl carbamates. Syntheses of 2,4-dioxo-3,4-dihydro-2H-1,3-benzoxazines and salicylamides
AUTHOR(S): Effenberger, Franz; Niess, Rolf; Schick, Max
CORPORATE SOURCE: Inst. Org. Chem., Univ. Stuttgart, Stuttgart, Ger.
SOURCE: Chem. Ber. (1972), 105(6), 1926-42
CODEN: CHBEAM
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Thermal rearrangement of N-aryl-substituted m-RC6H4O2CNHR1 (I, R = pyrrolidinyl, piperidino, or Me2N; R1 = Ph, Bz, or p-ClC6H4CO) obtained from m-RC6H4OH and R1NCO gave 4,2-R(HO)C6H3-CONHR1 (II), whereas N-alkoxy-substituted I gave 2,4-dioxo-3,4-dihydro-2H-1,3-benzoxazines (III). III were cleaved by dil. KOH with CO2 evolution to give II (R1 = H). The mechanism of this Fries rearrangement-like reaction involving an intramol. path is discussed.
IT **37893-32-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 37893-32-6 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 64 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1972:419657 CAPLUS
DOCUMENT NUMBER: 77:19657
TITLE: 2-[.alpha.[.omega.-(Dimethylamino)alkoxy]benzylidene]-4-methyl-2H-1,4-benzothiazin-3(4H)-ones
INVENTOR(S): Krapcho, John
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 29 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2150661	A	19720413	DE 1971-2150661	19711011
US 3715353	A	19730206	US 1970-80196	19701012
CH 561710	A	19750515	CH 1971-14807	19711011
FR 2110376	A5	19720602	FR 1971-36633	19711012
FR 2110376	B1	19750207		
HU 163946	P	19731128	HU 1971-SU678	19711012
JP 55018707	B4	19800521	JP 1971-80490	19711012
GB 1373537	A	19741113	GB 1971-47261	19711111

PRIORITY APPLN. INFO.: US 1970-80196 19701012

GI For diagram(s), see printed CA Issue.

AB Two title compds. (I, n = 2 or 3), useful as antidepressants, were prepd. by ring closure of o-H2NC6H4SH and ClCH2CO2H, N-methylation, benzoylation, and aminoalkylation. Thus, ClCH2CO2H was added to o-H2NC6H4SH in NaOH at <30.degree. and the mixt. refluxed 4 hr to give 82% II. NaH and then Me2SO4 were added to II in DMF at <30.degree., and the mixt. was heated 2 hr at 100-5.degree. to give 74% III. NaH was added to III and BzOMe in Me2SO and the mixt. heated 3 hr at 70-5.degree. to give 90% IV. NaH was added to IV in DMF, the mixt. heated at 45.degree., Me2NCH2CH2Cl in PhMe and then NaI were added at 25.degree., and the mixt. was heated 3 hr at 100-5.degree. to give I (n = 2), which was pptd. as hydrochloride and recrystd. as maleate in 31% yield.

IT **37142-84-0P 37142-85-1P 37142-86-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 37142-84-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[2-(dimethylamino)ethoxy]phenylmethylene]-4-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47451-15-0
CMF C20 H22 N2 O2 S



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.





RN 37142-85-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[2-(dimethylamino)ethoxy]phenylmethylene
]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 37142-86-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one,
2-[[3-(dimethylamino)propoxy]phenylmethylen
e]-4-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47494-87-1
CMF C21 H24 N2 O2 S



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L14 ANSWER 65 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1971:476816 CAPLUS
DOCUMENT NUMBER: 75:76816
TITLE: Substituted 2H-1,4-benzothiazine derivatives
INVENTOR(S): Krapcho, John
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 40 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2051474	A	19710506	DE 1970-2051474	19701020
BR 6915342	A0	19730313	BR 1969-215342	19691219
US 3746706	A	19730717	US 1970-35590	19700507
HU 163349	P	19730728	HU 1970-SU569	19701022
NL 7015698	A	19710503	NL 1970-15698	19701027
CH 543512	A	19731214	CH 1970-15877	19701027
FR 2070172	A1	19710910	FR 1970-38889	19701028
FR 2070172	A5	19710910		
GB 1334793	A	19731024	GB 1970-49269	19701028
CA 948626	A1	19740604	CA 1970-96805	19701028
JP 50022557	B4	19750731	JP 1970-95067	19701028
BE 774835	A1	19720503	BE 1971-110068	19711103

PRIORITY APPLN. INFO.: US 1969-871976 19691028
US 1970-35590 19700507

GI For diagram(s), see printed CA Issue.
AB Reacting I with R3MgBr gave antiinflammatory II. I (R1 = C2H4NMe2, R2 = Ph, Y = S) was treated with MeMgBr in THF at 20.degree. to yield II (R1 = C2H4NMe2, R2 = Ph, R3 = Ac, Y = S). An addnl. 16 examples involve this rearrangement in prepn.
IT **33216-62-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 33216-62-5 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-pyridinylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 66 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1971:449005 CAPLUS
DOCUMENT NUMBER: 75:49005
TITLE: Synthesis and central nervous system effects of some benzothiazinones
AUTHOR(S): Heindel, Ned D.; Reid, Jack R.; Willis, Joseph E.
CORPORATE SOURCE: Dep. Chem., Lehigh Univ., Bethlehem, Pa., USA
SOURCE: J. Med. Chem. (1971), 14(5), 453
CODEN: JMCMAR
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.

AB Six 2-carbomethoxy-methylene-3,4-dihydro-3-oxo-2H-benzo-1,4-thiazines were synthesized by condensing o-aminothiophenols with di-Me acetylene-dicarboxylate in MeOH, and tested in a neuropharmacol. mouse profile. Compd. I was inactive and nontoxic at doses of 1000 mg/kg, whereas compd. II induced a low order of sedativehypnotic activity at 1000 mg/kg but not at 300 mg/kg, is reflected in a depression of spontaneous motor activity and body tone and increases in passivity and pupil size. The most active compd. was III which induced depression, catatonia, and decreased motor activity at doses as low as 100 mg/kg.

IT **31385-17-8P 31385-18-9P 32723-06-1P 32723-08-3P 32816-83-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 31385-17-8 CAPLUS
CN Acetic acid, (3,4-dihydro-6-nitro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester (9CI) (CA INDEX NAME)



RN 31385-18-9 CAPLUS
CN Acetic acid, (3,4-dihydro-7-methoxy-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, methyl ester (9CI) (CA INDEX NAME)



RN 32723-06-1 CAPLUS
CN 2H-1,4-Benzothiazine-.DELTA.2,.alpha.-acetic acid, 6-chloro-3,4-dihydro-3-oxo-, methyl ester (8CI) (CA INDEX NAME)



RN 32723-08-3 CAPLUS
CN 2H-1,4-Benzothiazine-.DELTA.2,.alpha.-acetic acid, 7-ethoxy-3,4-dihydro-3-oxo-, methyl ester (8CI) (CA INDEX NAME)





RN 32816-83-4 CAPLUS
CN 2H-1,4-Benzothiazine-.DELTA.2,.alpha.-acetic acid, 7-chloro-3,4-dihydro-5-
methoxy-3-oxo-, methyl ester (8CI) (CA INDEX NAME)



L14 ANSWER 67 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1971:53750 CAPLUS
DOCUMENT NUMBER: 74:53750
TITLE: Synthesis of 1,5-benzothiazepine derivatives. II
AUTHOR(S): Kugita, Hiroshi; Inoue, Hirozumi; Ikezaki, Muneyoshi; Konda, Mikihiko; Takeo, Satoshi
CORPORATE SOURCE: Org. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd., Saitama, Japan
SOURCE: Chem. Pharm. Bull. (1970), 18(11), 2284-9
CODEN: CPBTAL
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Et threo-2-hydroxy-3-aryl-(2-nitroarylthio)propionates (I) (aryl = 4-RC6H4, R = H or p-MeO) were obtained by the reaction of 4,2-X(O2N)C6H3OH
(X = H or Cl) and Et arylglycidates(aryl = 4-RC6H4, R = H or p-MeO) in the
presence of catalytic amt. of NaHCO3. I was converted into 1,5-benzothiazepine derivs. (II), the configuration of which was 2,3-trans.
IT **30752-17-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 30752-17-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 68 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1971:42325 CAPLUS
DOCUMENT NUMBER: 74:42325

TITLE: Organic ulfur compounds. VII. Reactions of benzothiazine hydroxamic, acids
AUTHOR(S): Coutts, Ronald T.; Matthias, Sharon J.; Mah, E.; Pound, N. J.
CORPORATE SOURCE: Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, Alberta, Can.
SOURCE: Can. J. Chem. (1970), 48(23), 3727-32
CODEN: CJCHAG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Treatment of (3,4-dihydro-4-hydroxy-3-oxo-2H-1,4-benzothiazin-2-yl)acetic acid (I) with NaOH yields the corresponding lactam, i.e. (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-yl)acetic acid, together with the .alpha.,.beta.-unsatd. acid, 3,4-dihydro-3-oxo-2H-1,4-benzothiazine-.DELTA.2,.alpha.-acetic acid. The 6-Me and 6-Br derivs. of I behaved similarly when treated with NaOH but when 3,4-dihydro-4-hydroxy-3-oxo-2H-1,4-benzothiazine was so treated a more complex reaction occurred. Me (6-bromo-3,4-dihydro-4-hydroxy-3-oxo-2H-1,4-benzothiazin-2-yl)-acetate was also treated with HCl. The 2 products isolated were (6-bromo-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-yl)acetic acid and (6-bromo-7-chloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-yl)acetic acid. The action of HCl on 3,4-dihydro-4-hydroxy-7-methyl-3-oxo-2H-1,4-benzothiazine also gave 2 products. One was the corresponding lactam; the other was unexpected and has been tentatively identified as bis[2-(3,4-dihydro-7-methyl-3-oxo-2H-1,4-benzothiazine].

IT **30321-26-7P 30321-95-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 30321-26-7 CAPLUS
CN 2H-1,4-Benzothiazine-.DELTA.2,.alpha.-acetic acid, 3,4-dihydro-6-methyl-3-oxo- (8CI) (CA INDEX NAME)



RN 30321-95-0 CAPLUS
CN 2H-1,4-Benzothiazine-.DELTA.2,.alpha.-acetic acid, 6-bromo-3,4-dihydro-3-oxo- (8CI) (CA INDEX NAME)



L14 ANSWER 69 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1971:13117 CAPLUS
DOCUMENT NUMBER: 74:13117
TITLE: Synthesis of 1,5-benzothiazepine derivatives. I
AUTHOR(S): Kugita, Hiroshi; Inoue, Hirozumi; Ikezaki, Muneyoshi; Takeo, Satoshi
CORPORATE SOURCE: Org. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd.,

Saitama, Japan
SOURCE: Chem. Pharm. Bull. (1970), 18(10), 2028-37
CODEN: CPBTAL
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Reaction of 2-aminothiophenol and Et phenylglycidate gave Et 2-hydroxy-3-(2-aminophenylthio)-3-phenylpropionate (I) and 2-phenyl-3-hydroxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (II). Hydrolysis of I gave the corresponding amino acid which was cyclized to II. The reaction of 2-nitrothiophenol and Et 3-(4-methoxyphenyl)glycidate was also studied. The rearrangement of II to III was obsd.
IT **24545-07-1P**
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, from dihydrohydroxyphenylbenzothiazepinone)
RN 24545-07-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



L14 ANSWER 70 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1970:457129 CAPLUS
DOCUMENT NUMBER: 73:57129
TITLE: Effect of alkali on 8-benzoylaminothiacarbocyanine iodide
AUTHOR(S): Kiprianov, A. I.; Suleimanova, M. G.; Dyadyusha, G. G.
CORPORATE SOURCE: Inst. Org. Khim., Kiev, USSR
SOURCE: Ukr. Khim. Zh. (1970), 36(3), 269-72
CODEN: UKZHAU
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Bis(3-methylbenzothiazole-2)-8-benzoylaminothiacarbocyanine iodide (I) (0.5 g) yielded, after refluxing for 10 min with 0.1 g NaOH in 150 ml EtOH, evapn. of the solvent, and chromatographic purification on Al2O3 (C6H6 followed by CHCl3), 0.12 g 2,3-dihydro-4-methyl-2[(3-methyl-2-benzothiazolinylidene)ethylidene]-1,4-benzothiazin-3-one (II), m. 206.degree.. II was prepd. for comparison by condensing o-MeNHC6H4SH with ClCH(CO2Et)2 in alc.-NEt3 to form 2-carbethoxy-4-methyl-2,3-dihydro-1,4-benzothiazin-3-one (III), b1 198.degree., which was condensed with IV in boiling PhNEt2 for 30 min. Using o-H2NC6H4SH, the N-demethylated analogs of III, m. 145.degree., and of II, m. 274.degree., .lambda.max 444 nm (EtOH), were similarly prepd., but attempts to methylate the latter to II were unsuccessful. A mechanism for the formation of II was proposed.
IT **28731-98-8P 29430-90-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 28731-98-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[2-(3-methyl-2-benzothiazolinylidene)ethylidene]- (8CI) (CA INDEX NAME)



RN 29430-90-8 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 4-methyl-2-[2-(3-methyl-2-benzothiazolinylidene)ethylidene]- (8CI) (CA INDEX NAME)



L14 ANSWER 71 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1970:21702 CAPLUS
DOCUMENT NUMBER: 72:21702
TITLE: 2H-1,4-Benzothiazin-3(4H)-ones
INVENTOR(S): Krapcho, John
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger., Offen., 27 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1910302	A	19690925	DE 1969-1910302	19690228
US 3635956	A	19720118	US 1968-709808	19680301
GB 1265165	A	19720301	GB 1969-1265165	19690224
FR 2003038	A5	19691107	FR 1969-5409	19690228
FR 2003038	B1	19730810		
CH 493553	A	19700715	CH 1969-493553	19690228
JP 49010671	B4	19740312	JP 1969-15839	19690301
FR 2034449	A5	19701211	FR 1970-9282	19700316
FR 2034449	B1	19730810		

PRIORITY APPLN. INFO.: US 1968-709808 19680301
GI For diagram(s), see printed CA Issue.
AB The title compds. I (Y = S), useful as tranquilizers, were obtained by treating benzothiazin-3-one (II), prepd. from 2-aminothiophenol (III) and chloroacetic acid (IV), with an aldehyde and reacting the alkylidenebenzothiazine with a dialkylaminoalkyl halide. Thus, 95 g IV in 300 ml PhMe was added to 250 g III in 500 ml PhMe with stirring, and the mixt. refluxed 3 hr to give 64% II, m. 179-81.degree.. II (45 g), 45 g BzH, and 100 ml Ac2O was heated, 50 ml Et3N added, and the mixt. refluxed 7 hr to give 68% 2-benzylidene-2H-1,4-benzothiaz in-3(4H)-one (V), m. 203-5.degree.. Me2N(CH2)2Br (0.15 mole) in 200 ml PhMe was added to 4 g NaNH2 and 25.4 g V in 1 l. PhMe, the mixt. stirred 30 min at room temp. and t hen 4 hr at 60-5.degree.; treatment with HCl gave 56% I.HCl [X = H,

Y = S, ANB = Me2N(CH2)2, p = 0, R1 = Ph, (R2R3 =) O], m. 234-6.degree. (EtOH); the bromomethyl adduct, the 1-oxide, and the 1,1-dioxide were also prepd. Similarly prepd. were the following I.HCl [Y = S, (R2R3 =)O] (X, ANB, p, R1, % yield, and m.p. given): H, Me2N(CH2)3, 0, Ph, 70, 191-3.degree. (EtOH); H, Et2N(CH2)2, 0, Ph, -, 168-70.degree. (MeCN); H, Me2N(CH2)2, 1, Ph, -, 234-6.degree. (EtOH) (also reported was the corresponding .alpha.-methylcinnamylidene deriv.). 2-Cinnamylidene-2H-1,4-benzothiazin-3(4H)-one, m. 268-70.degree. (HCONMe2), was prepd. and used as an intermediate.

IT **24545-07-1P 24545-11-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 24545-07-1 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 24545-11-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-cinnamylidene- (8CI) (CA INDEX NAME)



L14 ANSWER 72 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1969:449871 CAPLUS
DOCUMENT NUMBER: 71:49871
TITLE: Structure and biogenesis of phaeomelanins. VII. Structure of trichosiderins
AUTHOR(S): Nicolaus, Rodolfo A.; Prota, Giuseppe; Santacroce, Ciro; Scherillo, Giulia; Sica, Donato
CORPORATE SOURCE: Univ. Napoli, Naples, Italy
SOURCE: Gazz. Chim. Ital. (1969), 99(4), 323-50
CODEN: GCITA9
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB The structure of a yellow-orange pigment C23H20N4O9S2 (I), extd. by dil. alkali from the feathers of the New Hampshire strain chicken was detd. I, heated in the presence of acid, is decarboxylated easily, yielding C22H40N4O7S2, having spectral and chromatographic properties identical with those of trichosiderins extd. from red human hair. The chem. behavior of some model compds. with trichosiderin-like chromophore was also investigated.

IT **23416-87-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 23416-87-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(2-benzothiazolylmethylene)- (8CI) (CA

INDEX NAME)



L14 ANSWER 73 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1968:12929 CAPLUS
DOCUMENT NUMBER: 68:12929
TITLE: Amidoalkylation of sulfazone
AUTHOR(S): Borovik, V. P.; Mamaev, V. P.
CORPORATE SOURCE: Inst. Org. Khim., Novosibirsk, USSR
SOURCE: Khim. Geterotsikl. Soedin. (1967), (2), 277-80
CODEN: KGSSAQ
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The title compd. (I) (2 g.) was dissolved at 120.degree. in a small amt. of AcOH, and 2.12 g. PhCH(NHAc)2 added, the mixt. heated 2 hrs., and AcOH evapd. To the residue ether was added followed by CHCl3 to give 41.5% 2-(.alpha.-acetamidobenzyl)sulfazone (II), m. 161-3.degree. (dioxane), To the CHCl3 filtrate petroleum ether was added to give 27% benzalsulfazone (III), m. 180.degree.. III was also obtained by heating I with BzH and Et3N 6 hrs. III with EtOH and 10% NaOH gave 64% 2-(.alpha.-ethoxybenzyl)sulfazone, m. 161-3.degree., and with MeOH gave 63% 2-(.alpha.-methoxybenzyl)sulfazone, m. 143-5.degree.. I (5 g.) with 5.31 g. PhCH(NHCONH2)2 was heated 2 hrs. to 125.degree. in 50 ml. AcOH, then AcOH evapd. in vacuo, MeOH added, and after few days 2-(.alpha.-ureidobenzyl)sulfazone (IV) m. 153-4.degree., pptd. in 41.5% yield. IV was also obtained in 21.8% yield by heating I with PhCH:NCONH2 in abs. EtOH with HCl. II hydrolyzed with 20% HCl gave 64% I.
IT **16684-63-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 16684-63-2 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 2-benzylidene-, 1,1-dioxide (8CI) (CA INDEX NAME)



L14 ANSWER 74 OF 74 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1967:94975 CAPLUS
DOCUMENT NUMBER: 66:94975
TITLE: On the structure of the product of the reaction of 2-aminothiophenol with diethyl acetylene dicarboxylate
AUTHOR(S): Kalbag, S. M.; Nair, Mohann D.; Rajagopalan, Parthasarathy; Talaty, Chandravadan N.
CORPORATE SOURCE: CIBA Res. Centre, Bombay, India
SOURCE: Tetrahedron (1967), 23(4), 1911-14

CODEN: TETRAB
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The major product (m. 220-2.degree.) of the reaction of 2-aminothiophenol with (.tplbond.CCO2Et)2 was conclusively shown to be 2-ethoxycarbonylmethylene-3,4 - dihydro - 3 - oxo - 2H - benzo - 1,4 - thiazine (I) and not 3-(ethoxycarbonylmethylene)-3,4-dihydro-2-oxo-2H-benzo-1,4-thiazine (II) as reported. CA 59, 39161.
IT **13677-06-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 13677-06-0 CAPLUS
CN Acetic acid, (3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:41:56 ON 19 MAY 2001)

FILE 'REGISTRY' ENTERED AT 09:42:02 ON 19 MAY 2001
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 0 S L1
L4 STRUCTURE UPLOADED
L5 QUE L4
L6 39 S L4

FILE 'STNGUIDE' ENTERED AT 09:44:37 ON 19 MAY 2001

FILE 'REGISTRY' ENTERED AT 09:49:50 ON 19 MAY 2001
L7 STRUCTURE UPLOADED
L8 QUE L7
L9 5 S L7
L10 STRUCTURE UPLOADED
L11 QUE L10
L12 26 S L10
L13 470 S L10 FUL

FILE 'CAPLUS' ENTERED AT 09:52:42 ON 19 MAY 2001
L14 74 S L13

=> d l10

L10 HAS NO ANSWERS
L10 STR



G1 C,N

G2 O,S,N

G3 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H

Structure attributes must be viewed using STN Express query preparation.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	312.95	449.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-43.51	-43.51

STN INTERNATIONAL LOGOFF AT 09:58:13 ON 19 MAY 2001

2-(1-(4-acetoxybutyl)-7-azaindol-3-yl)methylene-2H-1,4-benzothiazin-3(4H)-one



2-(1-(4-acetoxybutyl)-7-azaindol-3-yl)methylene-2H-1,4-benzothiazin-3(4H)-one